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Epidemiology: Bronchiolitis is the most common lower respiratory tract infection in infants. There is no specific diagnostic test for bronchiolitis. It is a viral
disease whose causative agents include most prominently RSV, human meta-pneumovirus, adenovirus and parainfluenza virus, although other viruses have been
implicated.
Diagnosis of bronchiolitis is made by a typical history and physical examination in the appropriate age group (infants and toddlers). It typically begins as an
apparent upper respiratory tract infection with sneezing, cough and congestion.
There may be diminished appetite and fever. This is followed by the gradual onset of respiratory distress frequently including paroxysmal cough, wheezing, and
tachypnea. Findings on physical examination often include wheezing and may include crackles, retractions, nasal flaring, grunting and a prolonged-expiratory
phase.
Objective of Guideline: To standardize the care of children who present for the first time with symptoms typical of bronchiolitis.
Target Users: Emergency Department/ Urgent Care Center (ED/UCC) physicians, General Pediatricians, Pediatric Nurse Practitioners
Guideline Inclusion Criteria: The guideline includes infants who are 2-24months of age presenting with the typical bronchiolitis presentation.
Guideline Exclusion Criteria: This guideline excludes infants with:







Asthma
Pneumonia
Airway compromise from foreign body or anatomic stricture or laxity
(vascular rings, tracheo- or bronchomalacia)
Congestive heart failure
Pertussis
GERD





Chronic aspiration
Inhalation injury
Cystic Fibrosis





Chronic lung disease
History of lower airway surgery
Immunodeficiency

Clinical Questions Answered by Guideline:
1. For the child being treated for the symptoms of bronchiolitis, what is the goal oxygen saturation that should be maintained?
2. Updated October 2016-For the patient who presents with the symptoms of bronchiolitis should inhaled hypertonic saline be used (see Appendix A)
3. For the child with bronchiolitis when should nasal suctioning (with a bulb tip) or nasopharyngeal suctioning (with a catheter) be used to clear secretions (see
Appendix B)
4. Updated October 2016-For the child who presents with the symptoms of bronchiolitis should high flow, high humidity nasal cannula be used (see
Appendix C)
5. Updated October 2016- For the child who presents with the symptoms of bronchiolitis should inhaled racemic epinephrine be used in the inpatient or
outpatient settings (see Appendix D)
6. For the child who presents with the symptoms of bronchiolitis should glucocorticoids be used in the inpatient or outpatient settings (see Appendix E)
7. For the child who presents with the symptoms of bronchiolitis should short acting beta agonists be used in the inpatient or outpatient settings (see Appendix
F)
8. For the child who presents with the symptoms of bronchiolitis should antibiotics be used in the inpatient or outpatient settings (see Appendix G)
9. For the child with bronchiolitis should laboratory tests and/or chest x-rays be obtained
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Differential Diagnosis:








Asthma
Pneumonia
Congestive heart failure
Pertussis
Congestive heart failure
GERD
Chronic aspiration








Inhalation injury
Cystic fibrosis
Chronic lung disease
History of lower airway surgery
Immunodeficiency (specifically lymphocytes < 2,500)
Obstructions involving large airways
o Foreign body in trachea or bronchus
o Vocal cord dysfunction
o Vascular rings
o Tracheomalacia, bronchomalacia

Practice Recommendations:
Physical Exam: The physical exam of a child presenting with suspected bronchiolitis focuses on respiratory symptoms including tachypnea, intercostal retractions
and sub-costal retractions. An expiratory wheeze and crackles, both coarse and fine may be heard on auscultation (Piedra & Stark, 2012). Oxygen saturation may
be < 95%. Upper respiratory congestion will be present.
Diagnostics: Bronchiolitis is diagnosed on the basis of the history and physical examination. There is no gold standard for diagnosing the disease. Although the
viral etiology may be identified (e.g. by viral culture, nucleic amplification testing, or rapid antigen testing), there is no specific test that confirms the diagnosis of
bronchiolitis itself. RSV rapid antigen testing, chest x-ray, complete blood counts, and basic metabolic panels may be indicated in specific clinical situations, though
there is no evidence for routinely obtaining these tests (Ralston et al., 2014).
Treatment:
 Inpatient and Outpatient
o Oxygen therapy to maintain oxygen saturation above 90%
o Suction- try least invasive technique first
o Antipyretic dosing
o Maintain hydration
o Topical anesthetic prior to needle procedure
 Inpatient
o Nebulized hypertonic (3%) saline as therapy for children who have increased need for mucociliary clearance. Discuss with the Respiratory
Therapist to follow the Respiratory Care Services Policy and Procedure to administer inhaled hypertonic saline
 Outpatient
o
A recommendation to use or not use racemic epinephrine cannot be made at this time
 Inpatient or Outpatient
o Evidence does not support routine use of the following, for either the inpatient or outpatient management of bronchiolitis:
 Glucocorticoids
 Antibiotics
 Laboratory tests
 Chest x-rays
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PICU Criteria: non-resolution or worsening of symptoms
o Recurrent apnea requiring close monitoring
o Severe respiratory distress
o Respiratory failure
o Hypoxemia (oxygen saturation < 90%) refractory to therapies that can provided on the inpatient units
Discharge Criteria: Resolution of respiratory distress and infrequent respiratory care needs:
o Respiratory rate for the infant is near 60 breaths per minute or less
 There is minimal to no increased work of breathing
 Stable without the need for nasopharyngeal suctioning for an adequate length of time
o Nutrition:
 The patient is able to maintain adequate hydration with oral feedings.
o Medication/Durable medical equipment:
 If the patient is receiving intravenous medications, convert to oral medications if the child will be going home on the medications
 Bulb syringe
o Social/Education:
 Parental comfort with discharge plans
 Family or caregiver has the resources to care for the child
 Parent education on:
 How to use a bulb syringe with or without nasal saline
 The expected course of illness - the course may be variable many children will have up to six weeks of cough and/or nasal
congestion
 The signs and symptoms of respiratory distress - increased respiratory rate or labored breathing (including abdominal breathing,
retractions, tracheal tug or nasal flaring)
 Home intervention when distress occurs - suctioning, fever control
 The signs and symptoms of dehydration - dry mouth, no tears, cool extremities, infrequent or small voids
 On admission, review Family Engagement handout
 Before discharge review the following KidsHealth material
 Bronchiolitis
 Bulb Syringe
 Fever
 Consider a referral to the Respiratory Outpatient Clinic (ROC Clinic) if the patient meets the clinic’s criteria.
 Contact the primary care physician about the discharge plans and arrange for follow up evaluation.

Measures:
Outcome:
% of bronchiolitis patients undergoing/receiving 1 or more of the Process Measures, below
Process measure:
% of patients diagnosed with bronchiolitis for which the provider ordered bronchiolitis education
% use of bronchiolitis power plan for patients diagnosed with bronchiolitis
% of bronchiolitis patients undergoing rapid RSV
% of bronchiolitis patients undergoing respiratory panel PCR
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% of bronchiolitis patients undergoing CBC
% of bronchiolitis patients undergoing blood culture
% of bronchiolitis patients undergoing chest x-ray
% of bronchiolitis patients receiving albuterol
% of bronchiolitis patients receiving systemic steroids
% of bronchiolitis patients antibiotic(s)
Balancing measure:
Length of stay
Readmissions within 72 hours
Cost
Potential Cost Implications:
 Potential cost savings with decreased use of medication and lab utilization.
Potential Organizational Barriers:
Training of staff on new procedures
 Use of hypertonic saline (inhaled) on inpatient units
 Change to nasal suction to preferred method, with nasopharyngeal as backup method to clear secretions
 New lower limit of oxygen saturation level for use of oxygen therapy
 Intermittent pulse oximetry after oxygen is discontinued on inpatient units
Clinical Questions Answered:
For all clinical questions, the Bronchiolitis Clinical Practice Guideline of the American Academy of Pediatrics (AAP) was adopted as our “parent” guideline. The
Guideline as assessed using the AGREE II Tool by three reviewers. For each domain contains three to eight questions, that are answered on a numeric scale,
range [1-7], higher is better.
Table 1.
AGREE II Tool Score
Domain

Domain 1 - SCOPE AND PURPOSE
Domain 2 - STAKEHOLDER INVOLVEMENT
Domain 3 - RIGOR OF DEVELOPMENT
Domain 4 - CLARITY AND PRESENTIATION
Domain 5 - APPLICABILITY
Domain 6 - EDITORIAL INDEPENDENCE
Overall Guideline Assessment

Percent
Agreement
100%
87%
96%
87%
53%
96%
90%
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Question 1: For the child being treated for the symptoms of bronchiolitis, what is the goal oxygen saturation that should be maintained?
Bronchiolitis Team Recommendation:
Outpatient and Inpatient
The Bronchiolitis Team recommends using supplemental oxygen to maintain an oxygen saturation ≥ 90%, based on the AAP statement for the care of the
patient with bronchiolitis (Ralston et al., 2014). Per the AAP statement, tolerance of oxygen saturation in the low 90% is influenced by acidosis, some
hemoglobinopathies, correct position of the O2 saturation probe, temporal relation to the last nasal clearance of secretions, and the infant’s work of
breathing. Oxygen supplementation may be administered when SaO2 is greater than 90% if any of these factors are present. We placed a high value on
assuring the comfort of the patient.
Question 2. Updated October 2016- For the patient who presents with the symptoms of bronchiolitis should inhaled saline be used?
Bronchiolitis Team Recommendation:
We concur with the Clinical Practice Guideline of AAP that makes a moderate recommendation that 3% nebulized hypertonic saline should not be
administered to infants and children in the Emergency Department, and further makes a weak recommendation that 3% nebulized hypertonic saline may
be administered to infants and children who are in the hospital (Ralston et al., 2014). Further research is likely to have an important influence on our
confidence in these recommnedations.
Literature (See Appendix A) supporting this recommendation: Twenty citations are included to answer this question. Sixteen are blinded RCT, and
four are open label RCT. All studies included in the AAP Guideline (Ralston et al. 2014) and studies published after the AAP Guideline literature search are
included.
Question 3: For the child with bronchiolitis, when should nasal suctioning (with a bulb tip) or nasopharyngeal suctioning (with a catheter) be used to clear
secretions?
Bronchiolitis Team Recommendation:
Outpatient and Inpatient
Based on low quality evidence, the Bronchiolitis CPG Team recommends the use of nasal suctioning/nasal aspiration as the primary route for removing
respiratory secretions. Nasopharyngeal (NP) suctioning may be used if signs of labored breathing continue after nasal suctioning. We placed high value
on amelioration of labored breathing and decreasing potential adverse effects of deep suctioning. One low quality study reports reduction in visible and
audible secretions with NP suctioning. However, a QI project completed at Children's Mercy Kansas by Jarvis et al (2012) showed similar hospital
readmission rates, admissions to the PICU, parental satisfaction, and average length of stay when nasal suctioning increased by 13% and NP suctioning
decreased by 15% over two bronchiolitis seasons. This recommendation may change when higher quality evidence becomes available.
Literature (See Appendix B) supporting this recommendation: No citations were found on searches of PubMed or CINAHL on bronchiolitis and
deep suctioning. However, 13 citations were located when searching CINAHL searching on just Bronchiolitis and suctioning. Of these articles, two articles
are included in this review. Additionally, a QI project conducted at Children’s Mercy Kansas informed this review.
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Question 4: Updated October 2016- For the child who presents with the symptoms of bronchiolitis should high flow, high humidity nasal cannula be used?
Bronchiolitis Team Recommendation:
We concur with the recommendation from the AAP Bronchiolitis Guideline, and cannot make a specific recommendation to use or not use HFNC. This is in
agreement with the Canadian Pediatric Society (Friedman et al., 2014), and the NICE Guidelines (NICE), 2015) as well. Further research on the efficacy
of HFNC, either in the PICU or on an inpatient unit is likely to have important influence on our confidence in making a recommendation.
Literature (See Appendix C) supporting this recommendation
Five publications are included for this topic. Guidelines from the AAP, the Canadian Pediatric Society, and the NICE Guidelines (Ralston et al., 2014;
Friedman et al., 2014;& NICE, 2015) along with a recent Cochrane Review (Beggs et al., 2014), and pre-post retrospective study (Riese, Firece, Riese, &
Alverson, 2015)
Question 5: Updated October 2016- For the child who presents with the symptoms of bronchiolitis should inhaled racemic epinephrine be used in the
inpatient or outpatient settings?
Bronchiolitis Team Recommendation
The AAP guideline recommends against the routine use of inhaled racemic epinephrine to treat acute bronchiolitis in both the inpatient and outpatient
settings (Ralston et al., 2014). However, the Bronchiolitis CPG Team concludes the evidence is insufficient at this time to make a recommendation for
against using racemic epinephrine.
Literature (See Appendix D) supporting this recommendation:
The meta-analysis by Hartling et al., (2011) was analyzed using GRADEprofiler (GRADEpro). The evidence is GRADED as Moderate to Low quality. Risk of
bias, specifically poorly reported allocation concealment and blinding were detected in the included studies. Studies were also inconsistent, which
decreases confidence in the pooled results. However for the following outcomes there was no difference in the following outcomes
 Length of stay: (N= 292) Mean difference = 0.35 days, (0.35 hours shorter to 0.17 hours longer)
 Admission at from first outpatient encounter to within 24 hours: (N= 995) RR= 0.67, 95% CI [0.5, 0.89]
 Admission overall, up to 7 days: (N= 835) RR= 0.81, 95% CI [0.63, 1.03]
Hartling et al., (2011) conclude that the evidence shows some reduction in hospital admission when children with bronchiolitis are treated with
epinephrine. However, the short term of medication effect and the differences in timing of outcome measurements limit the quality of the evidence.
There is no evidence to support the use of racemic epinephrine in the inpatient setting.
In a series of studies (Skjerven et al., 2013, 2015) report on the same group of subjects who received either inhaled racemic epinephrine versus normal
saline for acute bronchiolitis in the inpatient setting. In the first study, (Skjerven et al., 2013) LOS was not significantly between the two groups. In the
second study (Skjerven et al., 2015), the same subjects were evaluated approximately 2 years later. For those who received racemic epinephrine at the
acute bronchiolitis visit, a comparison was made between and went on to develop either recurrent bronchial obstruction, atopic eczema, or allergic
sensitization and those who did not develop these conditions. The outcome was the LOS at the acute bronchiolitis visit. There was no difference in LOS
between those who went on to develop atopic symptoms and those who did not.
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Question 6: For the child who presents for the symptoms of bronchiolitis should glucocorticosteriods be used in the inpatient or outpatient settings?
Bronchiolitis Team Recommendation:
Outpatient
Based on high quality evidence, the Bronchiolitis CPG Team recommends against the use of glucocorticoid steroids for the outpatient treatment of the
child who presents for the first time with the symptoms of bronchiolitis. We placed high value on avoiding exposure to a medication without evidence to
support its use. This recommendation can apply to most patients in most circumstances. Ten studies, summarized in a Cochrane Review (Fernandes et
al., 2010) showed that when glucocorticoids were given, hospitalization from the outpatient setting was not decreased. Children who received steroids
and were then admitted to the hospital did not have a shorter length of stay. However, there is an exploratory report from a large, high quality trial that
suggests combining systematic glucocorticoids (specifically dexamethasone) with epinephrine may significantly reduce hospital admissions. No short-term
adverse effects noted, and the trial was not designed to evaluate long-term effects. Further research is likely to change our confidence in the estimate of
the effect.
Inpatient
Based on high quality evidence, the Bronchiolitis CPG Team recommends against the use of glucocorticoid steroids for inpatient treatment of the child
who presents for the first time with the symptoms of bronchiolitis. We placed high value on avoiding exposure to a medication without evidence to
support its use. This recommendation can apply to most patients in most circumstances. Further research is likely to change our confidence in the
estimate of the effect.
Literature (See Appendix E) supporting this recommendation:
Sixty-four citations were found from the literature search. One Cochrane Database of Systematic Reviews (CDSR) paper is included (Fernandes et al.,
2010). Single studies identified in by the Bronchiolitis Team are included in the Fernandes 2010 CDSR, and are not reported upon separately.
Question 7: For the child who presents with the symptoms of bronchiolitis should short acting beta agonists be used in the inpatient or outpatient settings?
Bronchiolitis Team Recommendation:
Outpatient
Based on moderate to low quality evidence, the Bronchiolitis CPG Team recommends against the use of SABA for the outpatient treatment of the child
who presents for the first time with the symptoms of bronchiolitis. We placed high value on avoiding exposure to a medication without evidence to
support its use. This recommendation can apply to most patients in most circumstances. The Gadomski and Brower (2010) CDSR (included 15 low to
moderate quality studies) reported that the use of bronchodilators did not improve oxygen saturation as measured by pulse oximetry, clinical score,
decrease length of stay, or decrease time to resolution of illness
Inpatient
Based on high quality evidence, Bronchiolitis CPG Team recommends against the use of SABA for the inpatient treatment of the child who presents for
the first time with the symptoms of bronchiolitis. We placed high value on avoiding exposure to a medication without evidence to support its use. This
recommendation can apply to most patients in most circumstances. All studies identified by this CPG team were included in the Gadomski and Brower
(2010) CDSR. Gadomski and Brower (2010) reported from seven moderate quality studies that clinical score did not improve with the use of betaagonists. From 5 moderate quality inpatient studies, use of beta agonists did not decrease length of stay and from two moderate quality studies, use of
beta agonists did not affect time to resolution of illness, measured in days.
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Literature (See Appendix F) supporting this recommendation: Twenty one citations were found from the literature search. One CDSR paper is
included (Gadomski and Brower, 2010). Single studies identified in by the Bronchiolitis Team are included in the CDSR, and are not reported upon
separately.
Question 8: For the child who presents with the symptoms of bronchiolitis, should antibiotics be used in the inpatient or outpatient settings?
Bronchiolitis Team Recommendation:
Outpatient and Inpatient
Based on high quality evidence, the Bronchiolitis CPG Team recommends against the routine use of antibiotics for the child who presents for the first
time with the symptoms of bronchiolitis. The presence of secondary infection should be treated appropriately. The recommendation is based on the
CDSR by Spruling, Doust, Del Mar and Eriksson (2011). It included five studies- two high quality and three of moderate quality. The use of antibiotics did
not affect duration of symptoms, (at three days) length of stay for inpatients, re-admission rate or deaths.
Literature (see Appendix G) supporting this recommendation: Ninety-five studies were identified by the PubMed search, no unique articles were
added by the CINAHL search and one CDSR was located. The CDSR by Spruling, Doust, Del Mar and Eriksson (2011) is included in this review. No single
studies published since the CDSR were identified that answered this question.
Question 9: For the child with bronchiolitis should laboratory tests and /or chest x-ray be obtained?
Bronchiolitis Team Recommendation:
Outpatient and Inpatient
The Bronchiolitis CPG Team recommends against obtaining laboratory tests such as CBC & Diff w/platelets, Basic Metabolic Panel, Blood Culture, RSV
antigen detection, Flu A & B antigen, or chest x-ray for the infant who is presenting for the first time with symptoms of bronchiolitis. The
recommendation concurs with the AAP (2014) and Scottish Intercollegiate Guidelines Network (SIGN, 2009) bronchiolitis guidelines. RSV antigen testing
maybe obtained if applied to cohorting infants on inpatient units to prevent the spread of RSV. Bronchiolitis is diagnosed based on history and physical
examination (AAP, 2014). We placed high value on avoiding unnecessary medical testing and reduction of discomfort to the patient.
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Supporting Tools
Education Handouts:
 Family Engagement Handout
 KidsHealth- Bronchiolitis
 KidsHealth- Bulb Syringe
 KidsHealth- Fever
Procedures:

Nebulized 3% Hypertonic Saline for Bronchiolitis, CMH Respiratory Care Policy and Procedure
High Humidity/High Flow Nasal Cannula Administration, CMH Respiratory Care Policy and Procedure

Guideline Preparation: This guideline was prepared by The Office of Evidence Based Practice (EBP) in collaboration with content experts at Children’s Mercy
Hospitals and Clinics. Development of this guideline supports the Department of Clinical Effectiveness’s initiative to promote care standardization that builds a
culture of quality and safety that is evidenced by measured outcomes. If a conflict of interest is identified the conflict will be disclosed next to the team members
name.
Bronchiolitis Clinical Practice Guideline Team Members:
o Team Leaders:
o Kathleen Berg, MD
o Amanda Nedved, MD
Team
o
o
o
o
o

Members
Howard McCullough, RRT
Peggy Stokes, IS Analyst
Isaac Jonas, BS, Clinical Decision Support Data Analyst
Katie Burt, RRT, NPS, IS Data Analyst, III
Laura Diddle. BA, IS Data Analyst II

Office of EBP Team Members:
o Nancy Allen, MS, MLS, RD, LD, CNSC Evidence Based Research Specialist
o Jeff Michael, DO, FAAP
o Jackie Bartlett, PhD, RN
o Jarrod Dusin, MS, RD, LD, CNSC
o Dawn Watlington, Administrative Assistant
o Keri Swaggart, MLIS, AHIP Medical Librarian
o Evidence Based Practice Scholars
Guideline development funded by:
No external funding was obtained in the development of this guideline.
Development Process:
The review summary documents the following steps:
1. Review of existing internal and external guidelines and standards
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a. Internal guidelines: CMH Bronchiolitis Clinical Practice Guideline (2013)
b. External guidelines:
i. Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., Gadomski, A. M., . . . American Academy of Pediatrics. (2014). Clinical
practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics, 134(5), e1474-1502. doi:10.1542/peds.2014-2742
ii. National Institute for Health and Care Excellence (NICE), (2015). Bronchiolitis in children: Diagnosis and management. London: NICE.
iii. Friedman, J. N., Rieder, M. J., & Walton, J. M. (2014). Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to
24 months of age. Paediatric Child Health, 19(9).
iv. Scottish Intercollegiate Guidelines Network. (2009). Bronchiolitis in children. (ISBN 1 (10) 905813 01 5 Retrieved from http://www,sign.ac.uk
v. Texas Children’s Hospital. (2010). Bronchiolitis Clinical Guideline. Houston, Texas, USA: TCH Evidenced-Based Outcomes Center.
2. Review preparation
a. PICOT (Patient, Intervention, Comparison, Outcome, Type of question) questions established
b. Team leaders confirmed search terms employed by the Health Science Medical librarians, reviewed article titles and abstracts from the search, and
identified articles to be read and synthesized by the Evidence Based Practice Scholars.
3. Databases searched
a. AHRQ National Guideline Clearinghouse
b. Medline
c. CDSR
d. CINAHL
4. Critically analyze the evidence
a. Guidelines
i.
AGREE II criteria were used to analyze published clinical guidelines
b. Literature
i.
For single studies, the EBP Scholars used the Cochrane Collaborative’s electronic software, RevMan, to produce systematic reviews of the
evidence of the effects of healthcare and delivered these documents to the team for review. RevMan allowed the EBP Scholars to build the tables
of study characteristics, tables of study biases, and analyze study data in a meta-analysis.
ii.
When a meta-analysis was found in the literature search, or created in RevMan, the GRADE criteria evaluated the literature using GRADEpro to
assesses the meta-analysis for:
a. Limitations in study design and execution
b. Inconsistency between studies
c. Indirectness of study outcomes
d. Imprecision
e. Publication bias
f. The balance between desirable and undesirable effects
g. Patient values and preferences
h. Resource utilization
c. Table 2 defines how the quality of the evidence is rated and how the recommendation is established based on the type of evidence.
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Table 2. Grading of CPG Recommendations
Grade of
Confidence in Clarity
Recommendation
of Benefits vs Harms,
Burden, and Cost
Strong recommendation
Desirable effects clearly
High quality evidence
outweigh undesirable
effects or vice versa
Strong recommendation
Desirable effects clearly
Moderate-quality
outweigh undesirable
evidence
effect or vice versa

Quality of Supporting Evidence

Implications
Recommendation can apply to most patients in
most circumstances. Further research is unlikely to
change our confidence in the estimate of effect
Recommendation can apply to most patients in
most circumstances. Further research (if performed)
is likely to have an important effect on our
confidence in the estimate of effect and may
change the estimate.
Recommendation may change when higher-quality
evidence becomes available. Further research (if
performed) is likely to have an important influence
on our confidence in the estimate of effect and is
likely to change the estimate.
Recommendation may change when higher-quality
evidence becomes available; any estimate of effect,
for at least 1 critical outcome, is uncertain.

Strong recommendation
Low-quality evidence

Desirable effects clearly
outweigh undesirable
effect or vice versa

Consistent evidence from well-performed
RCTs or exceptionally strong evidence from
unbiased observational studies
Evidence from RCTs with important limitations
(inconsistent results, methodological flaws,
indirect evidence, or imprecise results) or
unusually strong evidence from unbiased
observational studies
Evidence for at least 1 critical outcome from
observational studies, from RCTs with serious
flaws or indirect evidence

Strong recommendation
Very-low-quality
evidence
(Very rarely applicable)

Desirable effects clearly
outweigh undesirable
effect or vice versa

Evidence for at least 1 of the critical outcomes
from unsystematic clinical observations or
very indirect evidence

Recommended
High-quality evidence

Desirable effects closely
balanced with
undesirable effects

Consistent evidence from well-performed
RCTs or exceptionally strong evidence from
unbiased observational studies

Recommended
Moderate-quality
evidence

Desirable effects closely
balanced with
undesirable effects

Recommended
Low-quality evidence

Desirable effects closely
balanced with
undesirable effects

Evidence from RCTs with important limitations
(inconsistent results, methodological flaws,
indirect evidence, or imprecise results) or
unusually strong evidence from unbiased
observational studies
Evidence for at least 1 critical outcome from
observational studies, from RCTs with serious
flaws or indirect evidence

Recommended
Very-low-quality
evidence

Desirable effects closely
balanced with
undesirable effects

Evidence for at least 1 critical outcome from
unsystematic clinical observations or very
indirect evidence

The best action may differ, depending on
circumstances or patients or societal values. Further
research is unlikely to change our confidence in the
estimate of effect.
Alternative approaches likely to be better for some
patients under some circumstances. Further
research (if performed) is likely to have an
important influence on our confidence in the
estimate of effect and may change the estimate.
Other alternatives may be equally reasonable.
Further research is likely to have an important
influence on our confidence in the estimate of effect
and is likely to change the estimate.
Other alternatives may be equally reasonable. Any
estimate of effect, for at least 1 critical outcome, is
uncertain.

Adapted from: Schunemann, H. J., Vist, G. E., Jaeschke, R., Kunz, R., Cook, D. J., & Guyatt, G. (2002). Advanced topics in moving from evidence to action:
Grading recommendations. In Guyatt, G., Rennie, D., Meade, M. O., & Cook, D. J.(Ed.), Users’ guides to the medical literature: A manual for evidence-based
clinical practice (pp 679-701). New York, NY:McGraw-Hill.
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5. Recommendations for the guideline were developed by a consensus process incorporating the three principles of EBP (current literature, content experts, and
patient and family preference, when possible).
Approval Process:
The original guideline was reviewed and approved by internal and external expert reviewers, the Content Expert Team, the Office of EBP, and other appropriate
hospital committees as deemed suitable for the guidelines intended use. This guideline update (October 2016) was reviewed and approved by the Content Expert
Team, the Office of EBP, and other appropriate hospital committees as deemed suitable for the guidelines intended use.
Disclaimer:
The content experts and the Office of EBP are aware of the controversies surrounding the Bronchiolitis Clinical Practice Guideline. When evidence is lacking or
inconclusive, options in care are provided in the guideline and the power plans that accompany the guideline.
These guidelines do not establish a standard of care to be followed in every case. It is recognized that each case is different and those individuals involved in
providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the
time.
It is impossible to anticipate all possible situations that may exist and to prepare guidelines for each. Accordingly these guidelines should guide care with the
understanding that departures from them may be required at times.
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Appendix A
Question 2. Updated October 2016- For the patient who presents with the symptoms of bronchiolitis should inhaled hypertonic saline be used?
Literature Summary:
Inpatient Length of Stay
Since the publication of the current AAP Guideline, two randomized control trails have been published that report on the outcome Inpatient Length of Stay
(LOS) (Everard et al., 2014; Silver et al., 2015). The results of the studies show no difference in inpatient hospitalization when infants and children with
bronchiolitis were treated with hypertonic saline versus those who received standard treatment, Mean Difference (MD) = 0.10, 95% CI [-0.26, 0.45] (See
Figure 2).
Studies above were pooled with studies prior to the AAP Guideline and analyzed using GRADE (Atkins et al., 2004).
1) Based on very low quality evidence hypertonic saline resulted in shorter inpatient LOS compared to standard care, MD = -0.53, 95% CI [-0.91, -0.14] (See
Figure 3).
a) However, when the studies are placed in subgroups based on the risk of selection bias (did they blind participants, personnel, and outcome assessors
and did they conceal the group to which subjects would be allocated?) Eight of the thirteen studies have low risk of selection bias, and five studies
have high risk of selection bias.
i) When studies with low risk of selection bias are analyzed as a subgroup, the mean difference in inpatient LOS for the same comparison was not
significant, MD = -0.37, 95% CI [-0.84, 0.09]. The included studies are graded as low quality evidence.
ii) When studies with unclear or high risk of selection bias are analyzed as a subgroup, the mean difference in inpatient LOS was significant, MD= 0.82, 95% CI [-1.32, -0.32]. The included studies are graded as very low quality evidence.
b) There is inconsistency among the studies. The I2 statistic is 81% and less than 50% is desired for this measure. The I2 statistic is a measure of
heterogeneity, it describes the percentage of variability in effect estimates that is due to heterogeneity rather than sampling error (chance). (Higgins
& Green, 2011).
Interpreting the I2 Statistic
Value

Interpretation
0% to 40%
Might not be important
30% to 60%
May represent moderate heterogeneity*
50% to 90%
May represent substantial heterogeneity*
75%-100%
Considerable heterogeneity
Note: * the importance of the observed I2 depends on (a) the magnitude and direction of effects and (d) strength of evidence for heterogeneity, either
or the P value from the chi-square test, or a confidence interval for I2. (Higgins & Green, 2011).
2) Based on moderate quality evidence hypertonic saline resulted in lower odds of hospitalization, OR = 0.63, 95% CI [0.45, 0.87] (See Figure 4). The
studies are graded down for imprecision, there are low number of events and the confidence intervals are wide. The I2 statistic is 0, which is desired
(Higgins & Green, 2011). Note the estimate of the effect is driven by one recent study, Wu et al. (2014). At this time the Bronchiolitis CPG team is
concurring with the AAP CPG that hypertonic saline should not be administered to infants with the diagnosis of bronchiolitis in the emergency
department (Ralston et al, 2014). Further research is likely to have an important influence on our confidence in the estimate of the effect and may
change the estimate.
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EBP Scholar’s responsible for analyzing the literature:
Shellie Brandon, LMSW-KS & MO
Teresa Bontrager, MSNed, BSN,RN, CPEN
Jennifer Foley, RT(R)(N), CNMT
Kori Hess, PharmD
Anne Holmes, MSN, MBA-HCM, RN, CCRC
David Keeler, BSN, RN, CPN
Joyce McCollum, RN, CNOR
Andrea Melanson, OTD, OTR/L
Helen Murphy, BHS, RRT AE-C
Robert Rhodes, MHA, RRT-NPS
Kim Robertson, MBA, MT-BC
Ashley Schuyler, RRT-NPS
EBP team member(s) responsible for reviewing, synthesizing, and developing this literature:
Nancy Allen, MS, MLS, RD, LD
Jarrod Dusin, MS, RD, LD, CNSC

Search Strategy and Results:

( (("Bronchiolitis, Viral/drug therapy"[Majr] OR "Bronchiolitis, Viral/prevention and control"[Majr] OR "Bronchiolitis, Viral/therapy"[Majr]) AND
("Respiratory Syncytial Virus Infections"[Mesh] OR "Respiratory Syncytial Virus, Human"[Mesh]) AND ((Humans[Mesh]) AND (English[lang]) AND (MetaAnalysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp] OR Review[ptyp] OR Consensus Development Conference[ptyp] OR
Guideline[ptyp]) AND ((infant[MeSH] OR child[MeSH] OR adolescent[MeSH])) )) AND "2015/06/13 15.00"[MHDA]:"2015/07/18 15.00"[MHDA]) Search
performed on July 18 2015. One study identified, and excluded, does not answer the question.
And
Sent on: Mon Apr 11 11:30:46 2016
Search: ("Saline Solution, Hypertonic"[Mesh] AND ("Administration, Inhalation"[Mesh] OR "Nebulizers and Vaporizers"[Mesh])) AND
("Bronchiolitis/therapy"[Mesh] OR "Respiratory Syncytial Virus Infections/therapy"[Mesh]) Filters: From 2013/01/01 to 2015/12/31
22 articles identified- the Zhang, L., Mendoza-Sassi, R. A., Klassen, T. P., and Wainwright, C. (2015) systematic review was selected, as other articles
identified in the search that answered the question are included in the systematic review.

Sent on Monday April 11 2016 10:48 AM
Search for bronchospasm as an adverse event of inhaled hypertonic saline
Search: (("Saline Solution, Hypertonic"[Mesh] OR "hypertonic saline") AND ("Administration, Inhalation"[Mesh] OR "Nebulizers and Vaporizers"[Mesh] OR
"inhaled" OR "nebulized")) AND ("Bronchial Spasm"[Mesh] OR "bronchospasm”)
17 articles returned, all excluded based on title and abstract.

14

Studies included in this review
Includes the following studies from Zhang 2013 Cochrane Review:
Al-Ansari, K., Sakran, M., Davidson, B. L., El Sayyed, R., Mahjoub, H., & Ibrahim, K. (2010). Nebulized 5% or 3% hypertonic or 0.9% saline for treating
acute bronchiolitis in infants. J Pediatr, 157(4), 630-634, 634 e631. doi:10.1016/j.jpeds.2010.04.074
Anil, A. B., Anil, M., Saglam, A. B., Cetin, N., Bal, A., & Aksu, N. (2010). High volume normal saline alone is as effective as nebulized salbutamol-normal
saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis. Pediatr Pulmonol, 45(1), 41-47. doi:10.1002/ppul.21108
Grewal, S., Ali, S., McConnell, D. W., Vandermeer, B., & Klassen, T. P. (2009). A randomized trial of nebulized 3% hypertonic saline with epinephrine in the
treatment of acute bronchiolitis in the emergency department. Arch Pediatr Adolesc Med, 163(11), 1007-1012. doi:10.1001/archpediatrics.2009.196
Ipek, I. O., Yalcin, E. U., Sezer, R. G., & Bozaykut, A. (2011). The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline
combination in moderate bronchiolitis. Pulm Pharmacol Ther, 24(6), 633-637. doi:10.1016/j.pupt.2011.09.004
Luo, Z., Fu, Z., Liu, E., Xu, X., Fu, X., Peng, D., . . . Yang, X. (2011). Nebulized hypertonic saline treatment in hospitalized children with moderate to severe
viral bronchiolitis. Clin Microbiol Infect, 17(12), 1829-1833. doi:10.1111/j.1469-0691.2010.03304.x
Luo, Z., Liu, E., Luo, J., Li, S., Zeng, F., Yang, X., & Fu, Z. (2010). Nebulized hypertonic saline/salbutamol solution treatment in hospitalized children with
mild to moderate bronchiolitis. Pediatr Int, 52(2), 199-202. doi:10.1111/j.1442-200X.2009.02941.x
Mandelberg, A., Tal, G., Witzling, M., Someck, E., Houri, S., Balin, A., & Priel, I. E. (2003). Nebulized 3% hypertonic saline solution treatment in hospitalized
infants with viral bronchiolitis. Chest, 123(2), 481-487.Everard, M. L., Hind, D., Ugonna, K., Freeman, J., Bradburn, M., Cooper, C. L., . . . Team, S.
S. (2014). SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax,
69(12), 1105-1112. doi:10.1136/thoraxjnl-2014-205953
Miraglia Del Giudice, M., Saitta, F., Leonardi, S., Capasso, M., Niglio, B., Chinellato, I., . . . Peroni, D. (2012). Effectiveness of nebulized hypertonic saline and
epinephrine in hospitalized infants with bronchiolitis. Int J Immunopathol Pharmacol, 25(2), 485-491Grewal, S., Ali, S., McConnell, D. W.,
Vandermeer, B., & Klassen, T. P. (2009). A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute
bronchiolitis in the emergency department. Arch Pediatr Adolesc Med, 163(11), 1007-1012. doi:10.1001/archpediatrics.2009.196
Ipek, I. O., Yalcin, E. U., Sezer, R. G., & Bozaykut, A. (2011). The efficacy of nebulized salbutamol, hypertonic saline and salbutamol/hypertonic saline
combination in moderate bronchiolitis. Pulm Pharmacol Ther, 24(6), 633-637. doi:10.1016/j.pupt.2011.09.004
Kuzik, B. A., Al-Qadhi, S. A., Kent, S., Flavin, M. P., Hopman, W., Hotte, S., & Gander, S. (2007). Nebulized hypertonic saline in the treatment of viral
bronchiolitis in infants. J Pediatr, 151(3), 266-270, 270 e261. doi:10.1016/j.jpeds.2007.04.010
Sarrell, E. M., Tal, G., Witzling, M., Someck, E., Houri, S., Cohen, H. A., & Mandelberg, A. (2002). Nebulized 3% hypertonic saline solution treatment in
ambulatory children with viral bronchiolitis decreases symptoms. Chest, 122(6), 2015-2020.
Tal, G., Cesar, K., Oron, A., Houri, S., Ballin, A., & Mandelberg, A. (2006). Hypertonic saline/epinephrine treatment in hospitalized infants with viral
bronchiolitis reduces hospitalization stay: 2 years experience. Isr Med Assoc J, 8(3), 169-173.
Studies added in the update:
Everard, M. L., Hind, D., Ugonna, K., Freeman, J., Bradburn, M., Cooper, C. L., . . . Team, S. S. (2014). SABRE: a multicentre randomised control trial of
nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax, 69(12), 1105-1112. doi:10.1136/thoraxjnl-2014-205953
Florin, T. A., Shaw, K. N., Kittick, M., Yakscoe, S., & Zorc, J. J. (2014). Nebulized hypertonic saline for bronchiolitis in the emergency department: a
randomized clinical trial. JAMA Pediatr, 168(7), 664-670. doi:10.1001/jamapediatrics.2013.5306
Jacobs, J. D., Foster, M., Wan, J., & Pershad, J. (2014). 7% Hypertonic saline in acute bronchiolitis: a randomized controlled trial. Pediatrics, 133(1), e8-13.
doi:10.1542/peds.2013-1646
Ojha, A. R., Mathema, S., Sah, S., & Aryal, U. R. (2014). A comparative study on use of 3% saline versus 0.9% saline nebulization in children with
bronchiolitis. J Nepal Health Res Counc, 12(26), 39-43.
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Pandit, S., Dhawan, N., & Deepak, T. (2013). Utility of Hypertonic Saline in the Management of Acute Bronchiolitis in Infants: A Randomised Controlled
Study. International Journal of Clinical Pediatrics, 2(1), 24-29. doi:doi: http://dx.doi.org/10.4021/ijcp96w
Silver, A. H., Esteban-Cruciani, N., Azzarone, G., Douglas, L. C., Lee, D. S., Liewehr, S., . . . O'Connor, K. (2015). 3% Hypertonic Saline Versus Normal Saline
in Inpatient Bronchiolitis: A Randomized Controlled Trial. Pediatrics, 136(6), 1036-1043. doi:10.1542/peds.2015-1037
Wu, S., Baker, C., Lang, M. E., Schrager, S. M., Liley, F. F., Papa, C., . . . Mason, W. H. (2014). Nebulized hypertonic saline for bronchiolitis: a randomized
clinical trial. JAMA Pediatr, 168(7), 657-663. doi:10.1001/jamapediatrics.2014.301
Zhang, L., Mendoza-Sassi, R. A., Wainwright, C., & Klassen, T. P. (2013). Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane
Database of Systematic Reviews(7). doi:10.1002/14651858.CD006458.pub3

Studies not included in this review with rationale for exclusion:

Study
(Canty & Colomb-Lippa, 2014)
(Jacobs, Foster, Wan, & Pershad, 2014)
(Legg & Cunningham, 2015)
(Li & Zhao, 2014)
(S. Ralston, Hill, & Martinez, 2010)
(Tinsa et al., 2014)

Reason for Exclusion
Clinicaltrial.gov; no results as of Aug 5 2016
Compared 7% saline to normal saline inhaled
Case study
All subjects were pretreated with ipratropium and budesonide X 2 then treated with 5%
hypertonic saline or normal saline
Retrospective cohort, looking for adverse events when used without SABAs
Does not answer this question; compares 5% saline to 5% saline with epinephrine
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Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (RevMan 5.3.5) was used to synthesize the included studies (Higgins & Green, 2011).
AGREE II (Brouwers et al., 2010) was used to assess the quality of AAP Guideline (Ralston et al., 2014).
The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) web based tool, The GDT, was used to grade the quality of the
included studies
Updated August 5, 2016, August 9 2016, Sept 16 2016
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Included Studies:
Total Number: 20 RCT
Blinded: 16 RCT
Non-blinded: 4 RCT

Quality Assessment of Included Studies:
Bias risk assessment factors: randomization concealment, patient selection, adequacy of blinding, and duration of follow-up
Number of Independent reviewers: 2

GRADE Analysis:
Number of independent reviewers: 2
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GRADE of the Included Studies for the Comparison, Nebulized Saline versus Control
Date: August 5, 2016
Question: Hypertonic Saline compared to Controls for Bronchiolitis

Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database of Systematic
Reviews 2008, Issue 4. Art. No.: CD006458. DOI: 10.1002/14651858.CD006458.pub2.

Quality assessment
№ of
studies

Study
design

Risk
of
bias

Inconsistency

Indirectness

№ of patients
Imprecision

Other
considerations

Effect

Hypertonic
Saline

Controls

Relative
(95%
CI)

Absolute
(95%
CI)

791

824

-

MD 0.53
lower
(0.91
lower to
0.14
lower)

Quality Importance

Inpatient LOS
13

randomized
trials

serious very
1
serious

2

not serious

not serious

none

⨁◯◯

CRITICAL

◯
VERY
LOW

Inpatient LOS - Low risk of selection bias
8

randomized
trials

not
very
serious serious

not serious

not serious

none

604

637

-

MD 0.37
lower
(0.84
lower to
0.09
higher)

serious

none

187

187

-

MD 0.82
lower
(1.32
lower to
0.32
lower)

3

⨁⨁◯◯ CRITICAL
LOW

Inpatient LOS - High or unclear risk of selection bias
5

randomized
trials

serious very
4
serious

5

not serious

6

⨁◯◯
◯
VERY
LOW

Odds of hospitalization from the ED
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Quality assessment
№ of
studies
7

Study
design
randomized
trials

Risk
of
bias

Inconsistency

not
not
serious serious

Indirectness
not serious

№ of patients
Imprecision
serious

6

Other
considerations
none

Hypertonic
Saline

Controls

121/455
(26.6%)

148/4
73
(31.3
%)

Effect

Quality Importance

Relative
(95%
CI)

Absolute
(95%
CI)

OR 0.66
(0.48 to
0.90)

82 fewer ⨁⨁⨁◯
per
MODER
1,000
ATE
(from 22
fewer to
134
fewer)

CI: Confidence interval; MD: Mean difference; OR: Odds ratio
1. For all thirteen studies, 5 (38%) have high or unclear risk for selection bias. Studies were either not randomized or allocation concealment was not
performed.
2. The means and standard deviations have poor overlap. For all of the included studies the I2 statistic is 81%. Less than 50% is desired.
3. The means and standard deviations of individual studies have poor overlap. For this group of studies, the I2 statistic is 83%. Less than 50% is desired
4. This group of studies are all high or unclear risk of selection bias. Either they were not randomized or, allocation concealment was not performed or
reported
5. The means and standard deviations of individual studies have poor overlap, although the I2 statistic is 54%.
6. The confidence intervals are wide.

20

Characteristics of Studies Tables

(Anil et al., 2010)
Methods
Participants

Prospective, randomized, double blind controlled trial Emergency Department
Setting: ED, recruitment from November 1 2005 to March 31 2006
Number randomized: 190 enrolled, 4 excluded prior to treatment, 186 were treated.
Number completed: N= 186
Gender: 24% Male
Age: 9.5 months
Inclusion criteria: Clinical severity (CS) score between 1-9 (range 0-12, lower is better) also known as the Wang score
Exclusion criteria: administration of study drug was delayed by 10 minutes or more (a protocol deviation),or if clinical
deterioration mandated withdrawal
Power analysis: for the detection of the difference of 1 using in the CS between the five treatment groups with an alpha of
0.05 and power of 80%, 30 subjects were needed per group, or 150 subjects total.

Interventions

All treatments were administered at 0 and 30 minutes using a facemask with continuous flow of 100% oxygen at 6 L/min
Treatment 1: 1.5 mg epinephrine in 4 ml of 0.9% saline n= 38
Treatment 2: 1.5 mg epinephrine in 4 ml of 3% saline n= 39
Treatment 3: 2.5 mg salbutamol in 4 ml of 0.9% saline n=36
Treatment 4: 2.5 mg salbutamol in 4 ml of 3% saline n= 36
Control: 4 ml 0.9% saline n= 37

Outcomes

Change in clinical severity score taken at 0, 30, 60 and 120 minutes.
Change in room air oxygen saturation,
Heart rate
Adverse Events- heart rate > 200, tremor, withdrawal from the study due to worsening clinical status, discontinuation of
medication due to side effects

Notes

Risk of bias table
Bias
Random sequence generation
(selection bias)

Scholars’
judgment
Low risk

Support for judgment
The investigators used a random number table in the sequence generation process
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Allocation concealment
(selection bias)

Low risk

Participants and investigators enrolling participants could not foresee assignment because only the study
coordinator was aware of allocation. Study solutions were identical in appearance and color.

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been
broken. Study solutions were identical in appearance and color. Identity of solutions was blinded.

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)
Other bias

Unclear risk
Low risk

Blinding of outcome assessment ensured. Intra-observer agreement for clinical severity scores was tested.
No missing outcome data
Insufficient information to permit judgment of ‘Low risk’ or ‘High risk’
The study appears to be free of all other sources of bias

(Everard et al., 2014)
Methods
Participants

SABRE study, multicenter, parallel-group RCT
Setting: 10 Pediatric wards and assessment units in England and Wales
Randomized into study: N=317
 Group 1: nebulized 3% HS group n=158
 Group 2: standard supportive bronchiolitis care n=159
Completed study:
 Group 1: n=149
 Group 2: n=141
Age: Infants less than 12 months
 Group 1: mean 3.4 months, SD 2.8
 Group 2: mean 3.3 months, SD 2.6
Gender, males:
 Group 1: 85 (57%)
 Group 2: 73 (51.4%)
Inclusion Criteria:
 Previously healthy infants less than 1 year of age.
 Admitted to hospital with a clinical diagnosis of acute bronchiolitis
 Requiring supplemental oxygen therapy on admission
 Consented and randomized within 4 hours of admission
Exclusion Criteria:
 Had wheezy bronchitis or asthma
 Had gastro-esophageal reflux (if investigated and diagnosed in hospital)
 Had previous lower respiratory tract infections (which required assessment in hospital).
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Had risk factors for severe disease (gestation of < 32 weeks, immunodeficiency, neurological and cardiac conditions,
chronic lung disease).
 Subjects for whom the carer’s English was not fluent and translational services were not available.
 Required admission to HDUs or ICUs at the time of recruitment
 involved in other research studies and this question was asked during the informed consent process, and for whom the
investigating team felt that it would have been inappropriate to include them in the study
Power analysis: 139 patients per group at a two-sided alpha-level of 5%
Location: United Kingdom
Interventions
Outcomes

Group 1: standard supportive care plus nebulized 3% HS solution, 4ml q 6 hours-oxygen as required, fluid administration
Group 2: Standard supportive bronchiolitis care- oxygen as required , minimal handling and fluid administration as appropriate
Primary outcomes:
 time to patient fit for discharge
 PICU admission
 Readmission within 28 days of discharge
Safety outcome:
 adverse events

Risk of bias table
Bias

Scholars’
judgment

Support for judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

High risk

Blinding of outcome
assessment (detection bias)

Low risk

No member of the study team had access to unblinded data sets or the unblinded reports until the final
analyses

Incomplete outcome data
(attrition bias)

High risk

There were some post randomization exclusions that are not defined. They did a sensitivity analysis and the
results were the similar
 Group 1: 16 exclusions
 Group 2: 10 exclusions

Selective reporting (reporting
bias)

Low risk

Other bias

use of central web-based randomization service
Randomization not revealed to anyone involved in patient recruitment/care
Did not blind

all outcomes (primary and secondary) have been reported

Unclear risk
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(Florin, Shaw, Kittick, Yakscoe, & Zorc, 2014)
Methods
Participants

Interventions

Randomized clinical trial ED
Setting: urban, tertiary care emergency department within a freestanding children's hospital
Randomized into study: N = 62
 Group 1: nebulized 3% hypertonic saline = 31
 Group 2: normal saline = 31
Completed study: N = 62
Gender, males:
 Group 1: 15
 Group 2: 13
Age, mean in months:
 Group 1: 7.2
 Group 2: 6.1
Inclusion Criteria:
 Children aged 2 to less than 24 months
 Presenting to emergency department (ED) with first episode of acute bronchiolitis
 Respiratory Distress Assessment Instrument (RDAI) score of 4 to 15, after albuterol treatment and no intention for
further respiratory therapy by ED physician in first hour after assessment
Exclusion Criteria:
Infants with:
 History of wheezing or asthma
 Bronchodilator therapy prior to the current illness
 Chronic lung or heart disease
 Critical illness
 Inability to receive nebulized medications
 Non-English-speaking guardians due to inability to provide fully informed consent within study time constraints
Power Analysis: 30 infants in each group to detect a mean change of 3 on the RACS between the groups, assuming ɑ = .05
and ß = .2 (80% power)



Group 1: 4mL of 3% HS (hypertonic saline)
Group 2: 4 mL of NS (normal saline)
1. All participants prior to confirmation of eligibility received standard therapy for bronchiolitis per the ED bronchiolitis
pathway, to include nasal suctioning and trial of single dose of nebulized albuterol
2. Study medications were delivered using a jet nebulizer with an oxygen flow rate of 8 L/min
3. Medication administration occurred within 90 minutes after albuterol administration
4. Respiratory scoring occurred at 1 and 2 hours after the study treatment
5. Brief parental surveys were performed at 1 and 2 hours after study treatment to gather information on respiratory
distress, ability to feed, and a medical history form was completed
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Outcomes

Primary Outcomes:
 Difference in mean RACS 1 hour after treatment demonstrated significantly less improvement in the HS group compared
with the NS group.
 No significant difference in the RDAI score at 1 hour between the 2 groups.
 No significant difference in RACS at 2 hours between the 2 groups.
Secondary Outcomes:
 No significant difference at 1 hour in change in heart rate or oxygen saturation between groups
 No significant difference between groups in rate of hospitalization or parental perception of child's breathing or feeding
status
 No adverse events occurred during the study.

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Support for judgment
Use of computer-generated random permuted block randomization
Central allocation (pharmacy-based) utilized
No study personnel, parents or guardians were aware of group assignments; both HS and NS are clear and
odorless so indistinguishable in syringe and nebulization chamber
Study clinicians performing scoring were unaware of group assignments
Intention to treat principle was used in data analysis of primary outcome
Protocol is available and all pre-specified outcomes were reported on

(Grewal, Ali, McConnell, Vandermeer, & Klassen, 2009)
Methods
Participants
Interventions

RCT ED
Infants 6 weeks to 12 months- mild to moderate bronchiolitis
Initial Respiratory Distress Assessment Instrument (RDAI) score was ≥4
Control group--2.5-mL aliquots of 0.9% normal saline+0.5mL of 2.25% racemic epinephrine --> total mixture of 3 mL was
given to the patient by nebulization.

25

Treatment group-- and 2.5-mL aliquots indistinguishable solution of 3% hypertonic saline + total mixture of 3 mL was given to
the patient by nebulization.
Each treatment was given by nebulizer with continuous flow of oxygen at 6 L/min.
Outcomes

Notes

Primary outcome: change in respiratory distress as measured by the Respiratory Assessment Change Score (RACS), from
baseline to 120 minutes.
Change in oxygen saturation
Secondary outcome: rate of hospital admission, return to emergency department.
Exclusion criteria were preexisting cardiac or pulmonary disease, previous diagnosis of asthma by a physician, any previous use
of bronchodilators (except for treatment of the current illness), severe disease requiring resuscitation room care, inability to take
medication using a nebulizer, inability to obtain informed consent secondary to a language barrier, or no phone access for
follow-up.

Risk of bias table
Bias

Scholars’
judgment

Support for judgment

Random sequence generation
(selection bias)

Low risk

Patients were randomized into blocks of 4. The randomization scheme was generated by the pharmacy using the
Web site Randomization.com

Allocation concealment
(selection bias)

Low risk

The randomization process was determined by the pharmacy. Physicians, house staff, nurses, study personnel,
and patients remained blinded to treatment allocation throughout the study.

Blinding of participants and
personnel (performance bias)

Low risk

The solutions were similar in appearance and smell, stored in identical syringes, labeled only by a code number,
The randomization list was concealed by the pharmacy until completion of the study

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)
Selective reporting (reporting
bias)
Other bias

Unclear risk

Used intention to treat analysis reported. One subject withdrew, from each group

Low risk
Unclear risk

Power analysis based on the ability to detect a change of 3 points in the RACS score.

(Ipek, Yalcin, Sezer, & Bozaykut, 2011)
Methods
Participants

RCT
Setting: the short-stay unit of the Pediatric Emergency Department or a training research hospital; October 2009-March 2010
Number randomized: 120 infants
Number completed: 120 infants
Age
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Gender
Inclusion criteria:
 < 2 years of age
 history of viral respiratory infection followed by wheezing and crackles on auscultation
 CBSS (severity score) of 4-8 (range 0-12, lower is better), also known as the Wang score
Exclusion criteria:
 CBBS < 4 or > 8
 oxygen saturation < 85% on room air
 chronic cardiac illness
 premature birth
 low birth weight < 2500 g
 severe immune deficiency
 severe neurological disease
 < 1 month or > 2 years
 consolidation or atelectasis on chest x-ray
Power analysis: not reported
Location: Turkey
Interventions

Outcomes

Supportive care, oxygen supplementation, aspiration, and hydration was provided to all as needed
Group 1: 4 ml of solution containing 0.15 mg/kg salbutamol plus normal saline
Group 2: 4 ml of solution containing 0.15 mg/kg salbutamol plus 3% saline
Group 3: 4 ml of solution containing only 3% saline
Group 4: 4 ml of solution containing normal saline
Primary:
Change in CBBS score
Secondary:
Corticosteroid need- when CBSS deteriorated and/or sao2< 85% on room air after the treatment
Hospitalization ratios
Clinical assessment at 48-72 hours

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

High risk

Allocation concealment
(selection bias)

High risk

Blinding of participants and
personnel (performance bias)

Low risk

Support for judgment
Patients were assigned to groups in a consecutive manner. The first patient went to Group 1, the second to
Group 2 etc.
Allocation was not concealed
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Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Physician doing follow up was blinded to study treatment
All completed

(Kuzik et al., 2007)
Methods

RCT multi-center study

Participants

Setting: multi-center study December 2003 to April 2006
Number randomized: 96
Number completed: 96
Age: Mean age 4.7 +/- 4.2 months, range [10 days to 18 months]
Gender: 57% male in the hypertonic saline group and 61% male in the normal saline group
Inclusion criteria:
 Moderately severe bronchiolitis
 History of viral upper respiratory infection
 Wheezing or crackles on chest auscultation
 Either an oxygen saturation (SaO2) < 94% or a severity score (RDAI, range 0-17, lower is better) of >/= 4.
Exclusion criteria:
 Previous episode of wheezing
 Chronic cardiopulmonary disease
 Immunodeficiency
 Illness that requires admission to the intensive care unit
 Use of nebulized hypertonic saline within previous 12 hours
 Premature birth (</= 34 weeks gestational age)
Power analysis: A reduction of LOS by one day was determined to be clinically significant. Sample size was calculated to be 46
subjects per arm for 80% power to show a p-value </= to 0.05
Location: Canada and United Arab Emirates

Interventions

Supportive care was provided to both groups, supplemental oxygen, aspiration, fluid administration
Treatment: 4 ml of 3% saline NEB every 2 hours for three doses, followed by every 4 hours for five doses, followed by every 6
hours until discharge
Control: 4 ml of normal saline NEB every 2 hours for three doses, followed by every 4 hours for five doses, followed by every 6
hours until discharge
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Outcomes

Primary: length of stay (definition- time from study entry to protocol- defined discharge criteria were met or independent
clinical grounds by the attending physician. The protocol defined discharge criteria included an RDAI score < 4 and an SaO2 of
>/= 95% on room air for 4 hours.

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Unclear risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Support for judgment
Computer-based randomization program
Double-blinded
Double-blinded
Study solutions were prepared by a research pharmacist and were identical in appearance and odor.
ITT, outcome data was reported
All specified outcomes were reported

(Luo et al., 2011)
Methods
Participants
Interventions
Outcomes

RCT
93 infants <24 months of age with viral bronchiolitis for the first time, China
Treatment: 2.5 mg salbutamol dissolved in 4.0 ml hypertonic (3%) saline
Control: 2.5 mg salbutamol dissolved in 4.0 ml normal (0.9%) saline
Wheezing remission time, cough remission time, pulmonary moist crackles and hospital time

Risk of bias table
Bias
Random sequence generation
(selection bias)

Scholars’
judgment
Unclear risk

Support for judgment
States random, but the randomization is not described
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Allocation concealment
(selection bias)

High risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of participants and key study personnel ensured. Identities of therapeutic packaging were not available
to investigators or attending physicians

Blinding of outcome
assessment (detection bias)

Low risk

Blinding of outcome assessment ensured. Identities of therapeutic packaging were not available to nursing or
medical staff

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Unclear risk

Other bias

The method of concealment is not described

No missing outcome data
Insufficient information to permit judgment of ‘Low risk’ or ‘High risk’. It is likely that the majority of studies will
fall into this category

Low risk

Luo 2011
Methods
Participants

Interventions

RCT
Setting: teaching hospital
Number randomized: 135 subjects
Number completed: 112 subjects, n= 57 in 3% saline group and n= 55 in the normal saline group
Age: range 1.5-10.1 month
Gender: 56% male
Inclusion criteria:
 < 24 months
 first episode of wheezing
 moderate to severe bronchiolitis by internal respiratory score
Exclusion criteria:
 > 24 months
 previous episode of wheezing
 chronic cardiac and pulmonary disease
 immunodeficiency
 accompanying respiratory failure
 require mechanical ventilation
 inhaling the nebulized 3% hypertonic saline 12 hours before this treatment
 prematurity (birth at < 34 weeks gestation)
Power analysis: not reported
Location: China
Supportive care was provided to both groups, supplemental oxygen, aspiration, fluid administration
Treatment: 4 ml of 3% saline NEB every 2 hours for three doses, followed by every 4 hours for five doses, followed by every 6
hours until discharge
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Control: 4 ml of normal saline NEB every 2 hours for three doses, followed by every 4 hours for five doses, followed by every 6
hours until discharge
Outcomes

Symptom relief
LOS
Clinical severity score

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Support for judgment
Computer generated
Concealed in an opaque sealed envelope

Seven patients in each group were discharged within 12 hours after enrollment, and not included in the
analysis. Including the subjects does not change the overall effect, only the confidence interval changes by a
small degree

(Mandelberg et al., 2003)
Methods
Participants

Randomized, double-blind, controlled-trial
Setting: Edith Wolfson Medical Center (Israel)
Randomized into study: n = 53
Completed study: n = 52
 Group 1: 0.9% NS + Epi = 25
 Group 2: 3% NS + Epi = 27
Gender, males (%):
 Group 1: 15 (60%)
 Group 2: 15 (55%)
Age in months (mean):
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 Group 1: 2.6
 Group 2: 3
Inclusion criteria: clinical presentation of bronchiolitis with temp > 30C who were admitted to hospital (specific diagnosis
criteria for bronchiolitis were not discussed)
Exclusion criteria: cardiac ds, chronic respiratory disease, previous wheezing episode, age > 12 months of age, oxygen
saturation < 85% on room air, obtunded consciousness, and/or progressive respiratory failure requiring mechanical ventilation
Power analysis: not reported
Interventions
Outcomes
Notes

Group 1: 0.9% Saline + 1.5 mg Epinephrine via nebulizer q8hr
Group 2: 3% Saline + 1.5 mg Epinephrine via nebulizer q8hr
Improvement in Clinical Severity Scores
Length of Stay



Percent of infants positive for RSV was not significantly different between groups
Eight eligible patients were excluded because their parents did not agree to sign informed consent (3 intended for 3%
group and 5 for 0.9% group) - randomized prior to consent???

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Unclear risk

Allocation concealment
(selection bias)

Unclear risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Low risk

Other bias

Unclear risk

Support for judgment
randomized in a "blinded manner" but no specifics on how this was accomplished
subjects "randomly assigned to one of two groups" but no specifics provided
attending physician responsible for discharging patient was blinded to treatment
no blinding of outcome assessment (length of stay - objective data)
outcomes reported on all subjects; 1 subject excluded due to clinical deterioration
pre-specified outcomes were reported as expected
it appears subjects were randomized prior to consent as authors reported 8 subjects were excluded (3 intended
for 3% group and 5 intended for 0.9% groups) because parents did not sign consent; when a sensitivity
analysis was done with and without the subjects in the denominators, it did not impact the statistical
significance of length of stay findings but is noteworthy none-the-less
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(Miraglia Del Giudice et al., 2012)
Methods
Participants

Interventions

RCT
Setting: Inpatients, less than 2 years with a clinical diagnosis of bronchiolitis.
Number randomized: 109 enrolled
Number completed: 106 completed. Three withdrew after randomization, and before treatment
Age: 4.5 months
Gender: 65% male
Inclusion criteria:
Clinical diagnosis
 first episode of wheezing
 symptoms of a viral respiratory infection
 Oxygen saturation < 94% in room air
 significant respiratory distress using the CSS (Wang) score (range 0-12, lower is better)
Exclusion criteria:
 pre-existing cardiac or pulmonary diseases
 premature birth < 36 weeks of gestational age
 previous diagnosis of asthma
 initial oxygen saturation of </= 85%
 respiratory distress severe enough to require resuscitation
Power analysis: Not reported
Location: Italy
All nebulized treatments included and oxygen and fluid therapy, as needed
Treatment group: nebulized 3% hypertonic saline with aerosolized epinephrine (1.5 mg)
Control group: nebulized 0.9% saline
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Outcomes

Primary:
Hospital length of stay
CSS score from baseline
CSS after epinephrine administration

Risk of bias table
Bias
Random sequence generation
(selection bias)
Allocation concealment
(selection bias)

Scholars’
judgment

Support for judgment

Low risk
Unclear risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Not described

Three who were randomized did not complete the study

NTC01238848
Methods
Participants

Interventions

RCT
Setting- Inpatient
Number randomized: N= 100 ; n= 50 in each group
Number completed: Total n= 82; n= 37 in the Treatment group and n= 45 in the control group
Gender: 50% male
Age: only reported as 1-24 months
Inclusion criteria: Infants aged 1-24 months, hospitalized for first episode of bronchiolitis , severity score >/= 5 and oxygen
saturation >/= 97%
Exclusion criteria: chronic respiratory or cardiovascular disease
Location: Argentina
Treatment: 3% hypertonic saline 3 ml nebulized + albuterol 0.25 mg/kg/d four times a day (QID), 5 days
Control: Normal saline,+ albuterol 0.25 mg/kg/d four times a day (QID), 5 days
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Outcomes

Primary: Hospitalization days
Secondary: length of oxygen use

Risk of bias table
Bias
Random sequence generation
(selection bias)
Allocation concealment
(selection bias)

Scholars’
judgment

Support for judgment

Low risk
Unclear risk

Blinding of participants and
personnel (performance bias)

High risk

Blinding of outcome
assessment (detection bias)

High risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Not described
Open label
Open label
18% did not complete the study. 26% in the treatment group and 10% in the control group

(Ojha, Mathema, Sah, & Aryal, 2014)
Methods
Participants

Double-blind RCT
Setting: Pediatric department of Kathmandu Medical College, Sinamangal, Kathmandu
Randomized into Study: Treatment Group (0.9% Saline) n = 36; Control Group (3% Saline) n = 36
Completed Study: Treatment Group N = 31; Control Group N = 28
Mean Age: Treatment = 8.51 months +/- 4.24; Control = 8.61 months +/- 5.742
Gender: 74% male
Inclusion Criteria:
 Children older than 6 weeks and below 24 months
 Clinical presentation of bronchiolitis for first time
Exclusion Criteria:
 Previous episodes of wheezing
 Chronic cardiac and pulmonary disease
 Immunodeficiency
 Accompanying respiratory failure requiring mechanical ventilation
 Inhalation of nebulized 3% hypertonic saline solution and salbutamol 12 hours before treatment
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 Premature infants born at less than 34 weeks gestation
 Those with oxygen saturation below 85% on room air
Power Analysis: PS-Power and Sample Size Calculator Version 3.0.43 was used to determine number of subjects in each
group. For this study "72:36 in case and control group" were needed.
Interventions

Outcomes

All patients were enrolled into the study within 24 hours of admission to hospital.
Patients in each group received the following:
 A minimum of 3 nebulization each day delivered at 8 hour intervals until discharge
 Additional nebulization or other treatment was left to the decision of the treating physician who was blinded to the
groups
 Supplemental oxygen was given when oxygen saturation fell below 92% on room air
 Clinical scores were obtained at treatment time and 30 minutes before the beginning of each inhalation session
Treatment Group: received inhalation of 4ml normal saline (0.9%)
Control Group: received inhalation of 4 ml hypertonic saline (3%)





A clinical score was recorded and included the following parameters: respiratory rate, wheezing, retraction, and oxygen
saturation
Length of hospital stay (calculated from time of entry into study to time of discharge)
Duration of oxygen supplementation
Time period required for clinical score to fall below 4 (Score range- 0-12, lower is better)

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting (reporting
bias)

Low risk

Other bias

Unclear risk

Support for judgment
Reported use of computer generated random number
Numbers were kept in sealed envelopes
0.9% and 3% saline were both kept in identical containers and labeled A and B. Labeling was done by a person
not associated with the study. Solutions were similar in appearance and smell
Randomization list was concealed until completion of study. Solution containers labeled A and B.
Thirty-six were required in each group, for a total of 72 subjects. 59/72 (82%) completed the study and are
included in the report.

Treatment and control groups appear to be reversed as defined in the Figure 1, although the article reports on
outcomes as defined in figure.
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(Pandit, Kim, Song, & Jeon, 2013)
Methods
Participants

Interventions

A Prospective, randomized controlled, non-blinded study.
Setting: 100 consecutive patients attending Paediatrics Emergency at a Government Multi Specialty Hospital Sector 16, India
during period from 1/11/2009 to 1/05/2011 (19 months)
Randomized into study: 100 consecutive patients attending Paediatrics Emergency at a GMSH between the age groups of 2
to 12 months and admitted with clinical diagnosis of acute bronchiolitis were enrolled in the study. Criteria for clinical diagnosis
of acute bronchiolitis were short history of cough with or without fever of less than seven days duration and wheezing on
examination and with first attack of wheezing.
Completed Study:
 Group A: 51 patients
 Group B: 49 patients
Gender, males: not reported
Age in months (range): 2 to 12 months
Inclusion Criteria:
Clinical diagnosis of acute bronchiolitis.
 Short history of cough with or without fever of less than seven days duration
 Wheezing on examination
 First attack of wheezing.
Exclusion Criteria:
 Patient with recurrent episodes of wheezing, one or more episodes of respiratory distress in the past
 Patients with family history of asthma, atopy
 Presence of congenital heart disease
 History of prematurity or mechanical ventilation in newborn period
 Very sick patients with shock, seizures, heart rate >100/min and adjudged to be in incipient respiratory failure.
 Grade III and IV PEM (PEM is not defined in the paper)
 Consolidation lung on X-ray chest
 No child to be included in the study twice.
Power Analysis: Based on the results of Kudzik et al., 2007, for the outcome length of stay, sample size of 100 subjects to
detect a difference with 80% power and an alpha of 0.05.


Group A: Hypertonic saline group, 4 mL of 3% hypertonic saline and 1 mL of 1,000 adrenaline was given as
nebulization with oxygen flow of 6-8 liter/min.
 Group B: (normal saline group), 4 mL of normal saline (0.9%) and 1 mL of 1:1,000 adrenaline was given as
nebulization.
The nebulization was given three times over three hours
 Assessment done before first treatment and after third treatment
 Respiratory rate
 Respiratory Distress Assessment Instrument (RDAI) score,
 Heart rate
 Oxygen saturation was done

37

Thereafter, nebulization was given every six hours to patients in each group until discharge and were assessed before and half
an hour after nebulization for their respiratory rate, RDAI, heart rate, oxygen saturation
Discharge criteria- respiratory rate less than 60/min, without any retractions and wheezing.
Outcomes

Primary outcomes:
 Length of hospital stay
Secondary outcomes:
 Improvement in RDAI score
 Respiratory rate
 Hemoglobin saturation
 heart rate
 Number of add on treatment
 Adverse events (defined as tachycardia, pallor, tremor, nausea, vomiting)
Group A: Hospital stay ranged from 1 to 10 days with mean stay of 3.9 days
Group B: Hospital stay ranged from 1 to 12 days with mean stay of 4.0 days.

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

High risk

Support for judgment
Computer generated sequence
Opaque envelopes for concealment, opened and then assigned to group
Non-blinded study design
Inpatients only

Blinding of outcome
assessment (detection bias)

High risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Non-blinded
No drop outs
authors reported on outcomes

(Sarrell et al., 2002)
Methods

Randomized, double-blind, controlled trial
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Participants
Interventions

65 ambulatory infants with viral bronchiolitis
Treatment: 0.5 ml (5mg) terbutaline in 2 ml of 3% saline solution
Control: 0.5 ml (5mg) terbutaline in 2 ml of 0.9% saline solution

Outcomes
Notes

Clinical Severity score (CS) described by Wang et al, Radiograph Assessment (RA) score described by Nasr et al
Israel

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Unclear risk

Allocation concealment
(selection bias)

Unclear risk

Support for judgment
Study states patients were randomly assigned to 1 of 2 groups; does not describe methodology.
Method of concealment is not described.

Blinding of participants and
personnel (performance bias)

Low risk

A code was placed on each "therapeutic package" which indicated control versus experimental. This code was
only available to the statistician.

Blinding of outcome
assessment (detection bias)

Low risk

Blinding of outcome assessment ensured, and unlikely that the blinding could have been broken. The code on
the therapeutic package was not available to the investigator or medical personnel.

Incomplete outcome data
(attrition bias)

Low risk

Missing outcome data balanced in numbers across groups. Authors performed intent to treat analysis which
they report was not different from reported per protocol results.

Selective reporting (reporting
bias)
Other bias

Unclear risk

Insufficient information to permit judgment of ‘Low risk’ or ‘High risk’.

Low risk

(Sharma, Thakur, Joshi, & Kulkarni, 2014)
Methods
Participants

Randomized, Double-blind study of Hypertonic (3%) Saline vs. 0.9% Saline Nebulization for Acute Viral Bronchiolitis
Setting: Tertiary care teaching hospital in India from Sept 2009-Dec 2010
Randomized into study: n = 250
Group 1: 0.9% Saline (NS) n = 125
Group 2: Hypertonic 3% Saline (HS) n = 125
Completed study: 248
Group 1: NS n = 123
Group 2: HS n = 125
Gender, males (%):

39

Group 1: NS 92 (75)
Group 2: HS 97 (78)
Age, years (SD):
Group 1: NS 4.18 (4.24)
Group 2: HS 4.93 (4.31)
Inclusion Criteria: Infants aged 1-24 months hospitalized with acute bronchiolitis (viral presentation) of moderate severity
(clinical severity score 3-6). Bronchiolitis was defined as first episode of wheezing along with upper rep tract infection including
rhinorrhea, cough, + low grade fever
Exclusion Criteria: children with obtunded consciousness, cardiac disease, chronic respiratory disease, previous wheezing
episode, progressive respiratory distress requiring respiratory support other than supplemental oxygen, and those having
received nebulized saline within the previous 12 hours
Power Analysis: Reduction in length of hospital stay of 1 day was previously proposed as being clinically significant. It was
anticipated that this would require a sample size of 113 patients in each arm.
Interventions
Outcomes

Notes

Group 1: 4 mL 0.9% saline + 2.5 mg salbutamol q4hr via conventional jet nebulizer with tight-fitting face mask
Group 2: 4 mL 3% saline + 2.5 mg salbutamol q4hr via conventional jet nebulizer with tight-fitting face mask
Primary Outcome: length of hospital stay defined as time from admission to reach clinical severity score < 3
Secondary Outcome: improvement in clinical severity scores at 12 hour intervals until discharge
Safety Outcome: no specific outcomes reported
Method of determining "clinical severity score" not defined in this study but references Wang, et al 1992
No adverse events related to nebulized therapy were reported by the parents, caregivers, or treating medical attendants in in
both groups

Risk of bias table
Bias

Scholars'
judgment

Support for judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

"No detectable difference in color, smell, or other physical properties between 0.9% saline and 3% hypertonic
saline"

Blinding of outcome
assessment (detection bias)

High risk

Outcomes were not blinded to the investigators completing the assessments; since the method of determining
the clinical severity score was not defined in this article it is unclear whether Outcomes were subjective and
therefore susceptible to considerable bias

Incomplete outcome data
(attrition bias)

Low risk

Primary and secondary outcomes were reported as anticipated

"Computer generated random numbers were used for enrollment in in consecutive manner"
"Combination code of therapeutic package was not available to investigator or treating staff"

Two patients were lost in final analysis but article does not elaborate; however, this is unlikely to affect results
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Selective reporting (reporting
bias)

Unclear risk

Pre-specified outcomes were reported; however the difference in clinical severity scores was reported only as
not statistically significant (data reported in line chart but individual scores not specified)

Other bias

Unclear risk

No funding or competing interests were reported

(Silver et al., 2015)
Methods
Participants

Interventions

Outcomes

Randomized control trial
Setting: Urban tertiary care children's hospital, November 2011 to June 2014
Number randomized: 227 randomized
Number completed: 190 completed the study
Gender: 64% male
Inclusion criteria:
 Physician diagnosis of bronchiolitis
 < 12 months old
Exclusion criteria:
 Treatment of asthma (corticosteroids or bronchodilators)
 Chronic cardiopulmonary disease such as bronchopulmonary dysplasia, cystic fibrosis
 Previous nebulized hypertonic saline < 12 hours before presentation
 Non-English, non-Spanish speaker
 Enrollment assessment> 12 hours after admission
 Patients previously enrolled within 72 hours of presentation
Power analysis:
105 subjects were needed in each arm to identify a 0.6 day change in length of stay, with 80% power with a 2-tailed test.
Alpha = 0.05.
Treatment group: 4 ml of nebulized 3% hypertonic saline every four hours from enrollment until hospital discharge
Control group: 4 ml of normal saline every four hours from enrollment until hospital discharge
All patients could receive study treatment every 2 hours pro re nata (PRN) with a maximum of 2 PRN dosages per 24 hour
period
Primary: length of stay defined as the time from the first study treatment to the time of hospital discharge or meeting
discharge criteria
Secondary:
Adverse events
 Seven-day readmission rates
 Clinical worsening- transfer to PICU or bronchospasm within 30 minutes of a nebulized study treatment, as indicated by
a RDAI score worsening by >/= to 4
Exit criteria:
 Respiratory Distress Assessment Instrument (RDAI) before and 30 minutes after the first study treatment as a safety
measure. An increase of >/= 4 points the patient received a bronchodilator and withdrawn from the study (n=1)
 Provider initiated bronchodilators or glucocorticosteriods (n=8)
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Notes

Transfer to PICU
Parent or guardian request

They included subjects with prematurity in both the treatment and control arms.

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

High risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Support for judgment
Computer generated
Investigational Drug Pharmacy was responsible of allocation
Study medications were indistinguishable from each other

Thirty-seven subjects did not complete the study, 20 from the treatment arm and 17 from the control arm. The
numbers in the flow diagram do not add up. They say they did a per protocol analysis, but go on to report an
intention to treat analysis for the LOS outcome. For the per protocol analysis, they did not meet power.

(Tal et al., 2006)
Methods

Double blind randomized control trial

Participants

Forty-four infants (< 12 months) hospitalized for acute viral bronchiolitis during the winter 2001-2002. There were 3 drop-outs,
41 subjects were included in the analysis.

Interventions

Control Group: Inhalation of 1.5mg epinephrine in 4mL of 0.9% (NS) every 8 hours during admission. N=20
Treatment Group: Inhalation of 1.5mg epinephrine in 4mL of hypertonic (3%) saline every 8 hours during admission. N=21.

Outcomes
Notes

1. Duration of hospitalization
2. Change in clinical score at the end of each day
The authors reported their own pooled data from previous study comparing hypertonic saline/epi compared to NS/epi
treatments. Both groups of participants were reported to have similar clinical characteristics and variables at baseline. The
authors report statistically significant data for duration of hospitalization and improved clinical scores after inhalation therapy.
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However, the treatments in the first study were administered by a different nebulizer which has shown to be less effective than
nebulizer used in follow up study.
Risk of bias table
Bias
Random sequence generation
(selection bias)

Scholars’
judgment
Unclear risk

Support for judgment
Authors do not report how the double-blind randomization was achieved

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Therapeutic modality not disclosed to medical personnel or investigator examining the participants on
admission and each subsequent day.

Blinding of outcome
assessment (detection bias)

Low risk

Decision to discharge patients made by attending physician each morning on rounds. Physicians blinded to
treatment modality

Incomplete outcome data
(attrition bias)

Low risk

Three participants not included in data analysis because 1) deterioration immediately after first treatment. 2)
Subject refused admission. 3) Subject required steroid treatment due to low cortisol levels. Subjects who
withdrew are not included in the analysis, and it is not clear to which group(s) they were assigned.

Selective reporting (reporting
bias)

Low risk

Reported on outcomes described. They added a short report on the pooled results from the similar study they
conducted the previous bronchiolitis season. Results from both cohorts were pooled- description of the previous
year study is not included, except it was "similar".

Other bias

Low risk

Volume, look, and smell of inhalation treatments were identical. Code was deposited by the statistician.

(Wu et al., 2014)
Methods
Participants

Double-blind randomized clinical trial
Setting: ED at 2 tertiary free-standing urban children's hospitals in California. Oakland and Los Angeles during bronchiolitis
season (November through April) March 1, 2008- April 30, 2011.
Number randomized: Hypertonic saline (HS) N= 211 and Normal saline (NS) N= 197
Number who completed the study: HS N=204 NS N=190
Gender= HS male=58.9% NS male=54.6%
Age: Younger than 24 months
Inclusion criteria:
 Primary diagnosis of viral bronchiolitis during bronchiolitis season
Exclusion criteria:
 prior illness with wheezing or bronchodilator use
 Premature - Born at less than 34 weeks
 cyanotic congenital heart disease
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Interventions

Outcomes

chronic lung disease
tracheostomy

Intervention: 2.5 mg of nebulized albuterol sulfate, followed by 4 mL of hypertonic saline via a small-volume wall nebulizer
Control:2.5 mg of nebulized albuterol sulfate, followed by 4 mL of normal saline via a small-volume wall nebulizer
 The ED physicians could order 2 additional treatments every 20 minutes to a maximum of 3 inhaled doses
 Admitted patients continued receiving study medication at a dosage of 4 mL every 8 hours until discharge




Admission rate was calculated as the number of patients requiring inpatient hospitalization divided by the total number
of patients randomized.
Length of stay was calculated as an integer value by subtracting the admission date from the discharge date.
The Respiratory Distress Assessment Instrument (RDAI) score was assigned by a study investigator before and
30 minutes after each treatment in the ED and once each morning of hospitalization This score was converted into the
Respiratory Assessment Change Score, which is calculated by adding together the change in RDAI score from before to
after treatment, plus a point for each 10% change in respiratory rate above 5% (e.g., −1 for a decrease of 6%-15%
and −2 for a decrease of 16%-25%; negative values signify improvement). Previous studies have determined a change
in RDAI of 4 points or greater or a change in Respiratory Assessment Change Score of 2 points or greater to be clinically
significant.

Risk of bias table
Bias

Scholars’
judgment

Random sequence generation
(selection bias)

Low risk

Allocation concealment
(selection bias)

Low risk

Blinding of participants and
personnel (performance bias)

Low risk

Blinding of outcome
assessment (detection bias)

Low risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Support for judgment
Computer-generated random number table stratified by site
Allocated by simple randomization to the HS or the NS group by the investigational pharmacy
Families, clinical staff, and study personnel were blinded to treatment allocation. Study medication was identical
in color, odor, and labeling.

Reasons for missing outcome data explained
Full protocol available
Study appears to be free of bias
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Figures

Figure 1. Risk of bias summary: Evidence Based Scholars’ judgments about each risk of bias item for each
included study for hypertonic saline administration

Note: Includes the following studies from Zhang 2013 Cochrane Review: (Al-Ansari et al., 2010); (Anil et al.,

2010); (Grewal, Ali, McConnell, Vandermeer, & Klassen, 2009) (Ipek, Yalcin, Sezer, & Bozaykut, 2011); (Kuzik et
al., 2007); (Luo et al., 2010); (Luo et al., 2011) (Mandelberg et al., 2003); (Sarrell et al., 2002); (Tal et al.,
2006).
The following studies, published since Zhang were added to the meta-analysis (Everard et al., 2014); (Florin,
Shaw, Kittick, Yakscoe, & Zorc, 2014); (Jacobs, Foster, Wan, & Pershad, 2014); (Miraglia Del Giudice et al.,
2012); NTCO1238848; (Ojha, Mathema, Sah, & Aryal, 2014); (Pandit, Dhawan, & Deepak, 2013; Silver et al.,
2015); and (Wu et al., 2014).

45

Figure 2. Hypertonic Saline vs. Control, Studies since the publication of Ralston et al. (2014), Outcome: Inpatient Length of Stay.
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Figure 3. Hypertonic Saline vs. Control, All studies, Outcome: Inpatient Length of Stay.
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Figure 4. Hypertonic Saline vs. Control, Outcome: Odds of Hospitalization from the ED.
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Appendix B
Question 3: For the child with bronchiolitis, when should nasal suctioning (with a bulb tip) or nasopharyngeal suctioning (with a
catheter) be used to clear secretions?
Critically Appraised Topic (CAT)

Synthesis of relevant studies:
Author,
date,
country,
and
industry of
funding
Conway2004

Jarvis, K.,
2012
USA

Patient Group

Level of
Evidence
(Oxford) /

Research design

Guideline
Infants <=
to 1 yr. old
with firsttime
admits of
Bronchioliti
s

Differential
Diagnosis/
Symptom
prevalence
4 study.

QI report

Comparison
of
suctioning
practices
before and
after the
implement
ation of a
suctioning
protocol

4

QI report

Significant results

Limitations

Guideline Implementation: Respiratory
Care for patients was considered
“Perfect” if bronchodilator administration
was PRECEDED by nasal suctioning and
the post-suctioning score was >/= 3 on
an internal scoring tool (scoring range 08)
Prior to guide-line implementation only
2% of the patients received “perfect”
respiratory care—following guideline
implementation “perfect care” increased
to 19%.
14% of the time SUCTIONING lowered the
Respiratory Score from >/= 3 to <3.
Measures
201020112011
2012
Season
Season
# Patients
894
483
% NP
30
16.6
suction
% times
nasal
70
83.4
suction
Readmit
4.28
3.93
rate
% pts on IV
46.5
35.1
fluid

Only infants </= to one year old –
first time episode of
uncomplicated bronchiolitis.
Exceptions patients with history of
cystic fibrosis, immunodeficiency,
CHD, BPD, congenital airway
issues, or need for mechanical
ventilation or other intensive
therapies warrant of PICU
admission.
Premature infants are included as
long as they had not underlying
exceptions stated above.
Number of patients in each group
varied due to a light bronchiolitis
season 2011-2012.
Retrospective
Compliance to protocol use was
not measured.
Quality project.
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Mallory,
2003
USA

None

Decision
analysis
level 5

Survey completed
by 519
physicians who
are members of
the AAP Section
of Emergency
Medicine and
living in the US.
Survey contained
1 of 4 vignettes
of an infant with
moderately
severe
bronchiolitis
followed by 17
questions about
the physician’s
diagnostic and
treatment
preferences and
perceptions of
the importance
of potential
treatments.
Vignettes were
identical except
for given Spo2
(94% or 92%)
and RR (50/min
or 65/min).

Admission
2
2
to PICU
Parental
satisfaction
2.94
2.94
(range 0-3,
3 best)
Avg. LOS
3.39
3.29
(d)
Use of Therapeutic Options:
o 96% of respondents would treat with
a bronchodilator. Variation in vignette
Spo2 or RR did not significantly affect
this decision.
o 82% would attempt to remove nasal
secretions for therapeutic reasons.
Variation in vignette Spo2 or RR did
not significantly affect this decision.
o 57% would administer supplemental
oxygen. Decision to administer oxygen
was more likely with the lower Spo2
(92%) and the higher RR (65).
o 9% would treat with a decongestant.
Variation in vignette Spo2 or RR did
not significantly affect this decision.
o 8% would treat with a corticosteroid.
o 9% would treat with an antibiotic.

o A survey is not an
assessment of actual clinical
practice
o Subjects received no
incentive for participation

Comparison of Therapeutic Options –
respondents were asked to rank the given
therapeutic options from 1 to 6, 1 having
the highest expected potential for positive
clinical effect.
o Nasal suction received the greatest
number of first-place rankings
o Bronchodilators 2nd place
o Supplemental oxygen 3rd place
Laboratory Tests:
o 61% of respondents would order a CXR
o 47% would order an RSV test
o 11% would order a CBC
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o
o
o
o
o
o
o

5% would order a blood gas analysis
4% would order a blood culture
4% would order serum electrolytes
3% would order a urinalysis
2% would order a urine culture
29% would not order any tests
Respondents who received a vignette
with Spo2 of 92% were slightly more
likely to order tests than those who
received a vignette with Spo2 of 94%.

Admission:
o 67% of all respondents indicated that
they would recommend admission.
o Respondents who received a vignette
with Spo2 of 92% were much more
likely to recommend admission.
o Respiratory rate was significantly
associated with admission preference
only when the vignette Spo2 was 94%
but not when the Spo2 was 92%.
Synthesis Author(s): EBP Scholars (Menown, J., Thompson, L., & Tobin, T.)
Date: 2012-05-03

CINAHL Search Strategy performed

AARC GUIDELINE: NASOTRACHEAL SUCTIONING
NTS 5.0 CONTRAINDICATIONS:
Listed contraindications are relative unless marked as absolute.
5.1 Occluded nasal passages1,6
5.2 Nasal bleeding1
5.3 Epiglottitis or croup (absolute)1,6
5.4 Acute head, facial, or neck injury1,2,6
5.5 Coagulopathy or bleeding disorder1,3,6
5.6 Laryngospasm1,3,6
5.7 Irritable airway1
5.8 Upper respiratory tract infection1
5.9 Tracheal surgery6
5.10 Gastric surgery with high anastomosis6
5.11 Myocardial infarction6
5.12 Bronchospasm2
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Appendix C
Question: Updated October 2016- For the child who presents with the symptoms of bronchiolitis should high flow, high humidity nasal
cannula be used?
Plain Language Summary from the Office of Evidence Based Practice:
Acute bronchiolitis is a common cause of visits to the Emergency Department and hospitalization of infants less than 2 years old. Symptoms of a
common cold, such as runny nose and congestion get worse, secretions increase, the child has difficulty breathing, coughs, and wheezes. The
usual treatment is providing supplemental oxygen, suctioning to remove nasal secretions, and providing fluids if dehydration is present. Recently,
supplying oxygen at a higher flow rate and adding humidity (high flow nasal cannula) has been suggested as a treatment to improve the child’s
breathing. This review compares the effects of high flow nasal cannula with standard oxygen administration in the care of the child with
bronchiolitis.
Two very low quality studies were identified that made the comparison of HFNC versus standard oxygen delivery and measured how long the child
stayed in the hospital. The results of the studies contradict each other. One study found no reduction in length of stay, while the other stated
children treated with HFNC had shorter time in the hospital.
Clinical Bottom Line:
There is insufficient evidence to determine the effectiveness of HFNC for the treatment of bronchiolitis in children < 2 years of age. This concurs
with the recommendations from the AAP (Ralston et al., 2014), the Canadian Pediatric Society (Friedman et al., 2014), and the NICE Guidelines
(NICE, 2015). Further research on the efficacy of HFNC, either in the PICU or on an inpatient unit is likely to have important influence on our
confidence in making a recommendation.
Literature Summary
The primary treatment for children who are admitted with bronchiolitis continues to be providing supplemental oxygen, suctioning to remove
secretions, and encouraging feedings. Conventionally, oxygen is delivered via low-flow nasal prongs. High flow nasal cannula allows the delivery
of a heated, humidified air/oxygen blend and oxygen at higher flows, which may improve ventilation. Flow rates of > 1 L/min to 5 L/min for
infants and up to 8 L/min in older children can be administered.
The Bronchiolitis Clinical Practice Guideline (CPG) of the AAP was adopted as the parent guideline of the Children’s Mercy Bronchiolitis CPG.
Application of the AGREE II tool to assess the AAP CPG yielded an overall agreement with the guideline of 90%. (See Table 1.) The AAP Guideline
states without completed RCTs on the efficacy of HFNC, they are unable to make a recommendation to use or not use the therapy (Ralston et al.,
2014).
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LOS
Since the publication of the AAP guideline, a Cochrane Review has been published (Beggs, Wong, Kaul, Ogden, & Walters, 2014). It includes one
very low quality study, Hilliard et al. (2012) a non-blinded RCT pilot study, that compared HFNC to oxygen therapy via an oxygen hood. The other
included study is a pre- post retrospective study (Riese, Fierce, Riese & Alverson, 2015). Both of the included studies reported on the outcome
length of stay (LOS). No harms were identified in either study.
The included evidence is very low quality. Hilliard et al. (2012) reports no difference in LOS between the treatment groups (n= 19) for the
comparison HFNC versus standard care (median time for HFNC 162 hours, range [96, 300) vs. hood oxygen 164 hours, range [84-233] p= 0.7.
Riese et al. (2015) report a significant difference (p < 0.001) in LOS comparing median, days, [IQR] of before the use of HFNC Median 4 [IQR 3,
5] versus post the use of HFNC
Median 3 [IQR 2, 4).
Characteristics of Included Studies

(Beggs et al., 2014)
Methods

Cochrane Review

Participants

Included one RCT- Hilliard 2012
Inclusion criteria
 RCTs or quasi -RCTs ( quasi allocation method such as date of birth would be accepted)
 Abstract reports ok
 Included infants < 24 months of age with a clinical diagnosis of bronchiolitis
Exclusion criteria
 Studies include infants with cardiorespiratory disease

Interventions

HFNC was defined as oxygen or oxygen/room air blend at flow rates > 4L/min via nasal cannula
HFNC compared with other forms of respiratory support
 Clinical and oxygen saturation monitoring
 Oxygen delivered by head box, mask or tent
 Oxygen delivered by low-flow nasal cannula (flow rate equal to or less than 4L/min
 Invasive intermittent positive pressure ventilation (IPPV)

Outcomes

Primary
 Need for IPPV or CPAP
 Length of time in the hospital or time until ready for discharge
Secondary
 Clinical severity score
 Duration of oxygen therapy or other form of respiratory support
 Oxygen saturation
 Respiratory rate
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Notes

Heart rate
Adverse events

See description below

(Hilliard et al., 2012)
Methods
Participants

Interventions

Prospective, randomized, open pilot study
Number included: N= 19
Gender: not reported
Age: median age 3 months, range [0.3-11.3]
Inclusion criteria: clinical diagnosis of moderately severe bronchiolitis
Exclusion criteria: not reported
Power analysis: not reported
Both groups: Oxygen concentration adjusted to achieve target pulse oximeter oxygen saturation (SpO 2) of 9296%
Treatment group: HFNC, n= 11
 Vapotherm 2000i at 4lpm with 100% oxygen and increased up to 8 lpm if tolerated.
 Continued for at least 24 hours then flow rate decreased sequentially and switched to dry oxygen once
2lpm.
Control group: oxygen hood : n=7

Outcomes

Notes

Primary outcomes
 SpO2 at 8 hours post randomization
 LOS, or time until ready for discharge

Only study included in the Beggs et al., (2014) a Cochrane SR/MA. The search strategy included records
published until May 15 2013.

Risk of Bias Table
Bias

Scholars'
judgment

Random sequence generation Unclear risk
(selection bias)

Support for judgment
Method to generate the sequence was not described
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Allocation concealment
(selection bias)

High risk

Authors did not disclose

Blinding of participants and
High risk
personnel (performance bias)

There was no attempt made to blind

Blinding of outcome
assessment (detection bias)

High risk

There was no attempt made to blind

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting Low risk
bias)
Other bias

High risk

All subjects completed the study
Not evident
The weaning protocols for the two treatments were different. The HFNC protocol had a slower
wean than did the head box oxygen protocol.

(Riese et al, 2015)
Methods
Participants

Retrospective, nonrandomized, pre-intervention vs post-intervention by chart review
Setting: USA, large urban children's hospital
Number Randomized: NOT randomized, but included total group size N= 290
1. infants <24 months of age
2. admitted to the PICU between April 1, 2010 and March 31, 2014
3. diagnosis of bronchiolitis by ICD9
1. 466.19 (not RSV bronchiolitis)
2. 466.11 (RSV bronchiolitis)
3. 786.03 (apnea)
4. 465.9 (acute upper respiratory infection)
5. V73.99 (unspecified viral illness)
4. n = 120 (24 months prior to protocol implementation)
5. n = 170 (24 months post protocol implementation)
Inclusion criteria:
 initially admitted to the PICU and received HFNC
Exclusion criteria:
 greater than 24 months of age (to reduce inclusion of non-bronchiolitis acute respiratory infections)
 hospitalizations greater than 21 days (to reduce inclusion of more complex cases)
 infant's with gestation of less than 37 weeks
 specific diagnosis of chronic lung disease
 asthma
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Interventions
Outcomes

Notes

chromosomal abnormalities
heart disease
neurological disease

Application of HFNC by a prescribed HFNC protocol
Primary:
 Length of stay after initiation of HFNC protocol
Secondary:
 Total hospital charges
 Intubation rates
 30 day readmission
HFNC defined as a flow >2 LPM and using a heated humidification device
Intervention Outcome Measures (Median and IQR interquartile range)
Median Total LOS (days)
Before: 4 (IQR 3-5)
After: 3 (IQR 2-4)

p <0.001

Median Total Hospital Charges
Before: $12,257 (IQR 8,365-17,226)
After: $9,337 (IQR 6,882-12,624)

p <0.001

Intubation (Adverse Outcome)
Before: 9/120 (7.5%)
After: 11/170 (6.5%)
p= 0 .73
30-d Readmission (Adverse Outcome)
Before: 11/120 (9.2%)
After: 13/170 (7.7%)
p= 0.64
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Appendix D
Question 5: Updated October 2016- For the child who presents with the symptoms of bronchiolitis should inhaled racemic
epinephrine be used in the inpatient or outpatient settings?
Bronchiolitis Team Recommendation
The AAP guideline recommends against the routine use of inhaled racemic epinephrine to treat acute bronchiolitis in both the inpatient
and outpatient settings (Ralston et al., 2014). However, the Bronchiolitis CPG Team concludes the evidence is insufficient at this time to
make a recommendation for against using racemic epinephrine.
The meta-analysis by Hartling et al., (2011) was analyzed using GRADEprofiler (GRADEpro). The evidence is GRADED as Moderate to
Low quality. Risk of bias, specifically poorly reported allocation concealment and blinding were detected in the included studies. Studies
were also inconsistent, which decreases confidence in the pooled results. Hartling et al., (2011) conclude that the evidence shows some
reduction in hospital admission when children with bronchiolitis are treated with epinephrine. However, the short term of medication
effect and the differences in timing of outcome measurements limit the quality of the evidence. There is no evidence to support the use
of racemic epinephrine in the inpatient setting. See the GRADE table below.
In a series of studies (Skjerven et al., 2013, 2015) report on the same group of subjects who received either inhaled racemic epinephrine
versus normal saline for acute bronchiolitis in the inpatient setting. In the first study, (Skjerven et al., 2013) LOS was not significantly
between the two groups. In the second study (Skjerven et al., 2015), the same subjects were evaluated approximately 2 years later. For
those who received racemic epinephrine at the acute bronchiolitis visit, a comparison was made between and went on to develop either
recurrent bronchial obstruction, atopic eczema, or allergic sensitization and those who did not develop these conditions. The outcome
was the LOS at the acute bronchiolitis visit. There was no difference in LOS between those who went on to develop atopic symptoms and
those who did not.
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GRADEpro Table:
Quality assessment
(Hartling et al., 2011)

No of patients

Effect

Quality Importance
Relative
No of
Risk of
Other
Epinephrine
Design
Inconsistency Indirectness Imprecision
Control (95% Absolute
studies
bias
considerations vs placebo
CI)
Length of Stay (inpatients only) (range of scores: 2.45-2.9; Better indicated by lower values)
2
randomized serious1 no serious
no serious
no serious
none
149
143
MD 0.35
CRITICAL
trials
inconsistency indirectness imprecision
lower MODERATE
(0.87
lower to
0.17
higher)
Admission at enrollment or <24 hours (outpatient only (assessed with: Count)
6
randomized serious2,3 no serious
no serious
no serious
none
62/493
93/502 RR 0.67 61 fewer
CRITICAL
trials
inconsistency indirectness imprecision
(12.6%) (18.5%)4 (0.5 to per 1000 MODERATE
0.89) (from 20
fewer to
93 fewer)
Admissions overall up to 7 days (outpatient only) (assessed with: Count)
3
randomized no
serious5
no serious
serious6
none
88/437
110/438 RR 0.81 48 fewer
CRITICAL
trials
serious
indirectness
(20.1%)
(25.1%) (0.63 to per 1000
LOW
risk of
1.03) (from 93
bias
fewer to
8 more)
Outpatient clinical score at 60 minutes (Better indicated by lower values)
6
randomized no
no serious
no serious
no serious
none
490
485
MD 0.73
CRITICAL
trials
serious inconsistency indirectness imprecision
lower
HIGH
risk of
(1.13 to
bias
0.33
lower)
1
One study had high risk for selective reporting bias.
2
Poorly reported allocation concealment
3
Poorly reported blinding technique
4
Chose the mean baseline risk as the variation in risk was similar across studies (~20%), except one study where it was 75%. (Ralston 2005a)
5
One study varied the saline concentration of the epinephrine carrier as well
6
Low number of events

58

(Skjerven, et al, 2013)
Methods

An eight center, randomized double blind trial with a 2 by 2 factorial design; inpatients

Participants

Setting: Eight centers in Norway
Number randomized: N= 404; n= 203 in the treatment group and n= 201 in the control group
Enrollment only occurred as long as a physician and nurse were available.
Number completed: N=321; n= 167 in the treatment group and n= 154 in the control group
Gender: 59% male
Inclusion criteria: moderate bronchiolitis (score of 4 or greater on a scale of 0-10, lower is better); less than 12
months old;
Exclusion criteria: any serious cardiac, immunologic, neurologic, or oncologic disease; serious respiratory
disease other than bronchiolitis; more than one previous episode of obstructive airway disease; symptoms of
lower airway disease (i.e. coughing) for more than 4 weeks; treated with glucocorticosteriod within the previous 4
weeks
Power analysis: 176 subjects in each medication group would provide a power of 80% at an alpha level of 0.05

Interventions

Treatment group: Weight based - 10 ml of racemic adrenaline dissolved in 0.9% saline to form a solution of 20
mg per mL
 < 5 kg- 0.10 mL
 5 to 6.9 kg 0.15 mL
 7 to 9.9 kg, 0.20 mL
 10 kg or more 0.25 mL
Control group: 0.9% saline alone

Outcomes
Notes

Primary: LOS- definition time from the first study inhalation until discharge from the hospital
Secondary: clinical score 30 minutes after the first inhalation, use of nasogastric feeding,
Cannot enter data into data table. The difference in LOS in children who received RE (n=203) = 63.6 hours,
Range [46.2-81.0[; while the range of those who received normal saline was 64.1 hours, range [49.8, 86.4]. The
Difference = 4.5, 95% CI [-6.5-15.5] and is not significant p= 0.42
There was a significant difference between subjects who received either treatment on a "On Demand" schedule
vs. a "Fixed" schedule. Here the Difference = 13.7, 95% CI [2.9, 2424].

Risk of bias table
Bias
Random sequence generation
(selection bias)

Scholars'
judgement
Low risk

Support for judgement
Block of eight, assignment to one of four study groups- randomization occured at a central site
1. RE scheduled
2. Placebo scheduled
3. RE intermittent
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4. Placebo intermittent
Allocation concealment
(selection bias)

Low risk

Used a list of study number for use for consecutive assignment

Blinding of participants and
personnel (performance bias)

Low risk

All treatments were prepared in an off-site pharmacy

Blinding of outcome
assessment (detection bias)

Unclear risk

Incomplete outcome data
(attrition bias)

Low risk

Selective reporting (reporting
bias)

Low risk

Other bias

Low risk

Author did not disclose
20% did not complete the study for various reasons, but the analyzed the primary outcome with
intention to treat analysis

(Skjerven et al., 2015)
Methods

This is a follow up study of Skjerven 2013. Looking at the treatment response in infancy was different when
subjects were ~ 2 years of age and had recurrent bronchial obstruction, atopic eczema, or allergic sensitization.
It is an eight center, randomized double blind trial with a 2 by 2 factorial design; inpatients

Participants

Setting: Eight centers in Norway
Number randomized: N= 404; n= 203 in the treatment group and n= 201 in the control group
Enrollment only occurred as long as a physician and nurse were available.
Number completed: N=321; n= 167 in the treatment group and n= 154 in the control group
Gender: 59% male
Inclusion criteria: moderate bronchiolitis (score of 4 or greater on a scale of 0-10, lower is better); less than 12
months old;
Exclusion criteria: any serious cardiac, immunologic, neurologic, or oncologic disease; serious respiratory
disease other than bronchiolitis; more than one previous episode of obstructive airway disease; symptoms of
lower airway disease (i.e. coughing) for more than 4 weeks; treated with glucocorticosteriod within the previous 4
weeks
Power analysis: 176 subjects in each medication group would provide a power of 80% at an alpha level of 0.05

Interventions

Treatment group: Weight based - 10 ml of racemic adrenaline dissolved in 0.9% saline to form a solution of 20
mg per mL
 < 5 kg- 0.10 mL
 5 to 6.9 kg 0.15 mL
 7 to 9.9 kg, 0.20 mL
 10 kg or more 0.25 mL
Control group: 0.9% saline alone
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Outcomes

Notes

Primary: LOS- definition time from the first study inhalation until discharge from the hospital, strafifed by
subgroups identified 2 years later. Sub groups were patients with and without recurrent bronchial obstruction,
atopic eczema, or allergic sensitization by 2 years of age
Cannot enter data into data table. When the data was re analyzed (~ 2 years) after the subjects could be
separated into subgroups of those who had recurrent bronchial obstruction, atopic eczema, or allergic
sensitization, no effect was seen in the LOS between those who developed atopic disease and received RE or not.
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Figures:

Figure: Risk of Bias Summary for included studies for racemic epinephrine and bronchiolitis.

Note: includes the following studies from Hartling, Wiebe, Russell, Patel and Klassen (2011) – Anil, 2010; Hariprakash 2003; Langley 2005; Mull
2004; Plint 2009; Ralston 2005: Wainright 2003; Walsh 2008. Skjerven 2013 and Skjerven 2015 were added to the meta-analysis for this
guideline.
Synthesis Authors:
EBP Scholars: Menown, J., Pirvu, D., Shubat, S. J., Tobin, T.
Office of EBP: Allen, N. H.,
Date: October 5 2016
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Appendix E
Question 6: For the child who presents for the symptoms of bronchiolitis should glucocorticoids be used in the inpatient or
outpatient settings?

GRADEpro Table:
Quality assessment

No of patients

Effect

Quality Importance
Glucocorticoids
Relative
No of
Risk of
Other
Design
Inconsistency Indirectness Imprecision
(systemic and Control (95% Absolute
studies
bias
considerations
inhaled)
CI)
Outpatient- Admission by day 1 (follow-up mean 1 days; assessed with: count)
10
randomized no
no serious
no serious
no serious
none
205/907
20% RR 0.92 16 fewer
CRITICAL
trials
serious inconsistency indirectness imprecision
(22.6%)
(0.78 to per 1000
HIGH
risk of
1.08) (from 44
bias1
fewer to
16 more)
Outpatient- Admission by day 7 (follow-up 7 days; assessed with: count)
6
randomized no
no serious
no serious
no serious
none
231/787
251/743 RR 0.86 47 fewer
CRITICAL
trials
serious inconsistency indirectness imprecision
(29.4%)
(33.8%) (0.7 to per 1000
HIGH
risk of
1.06) (from 101
bias2
fewer to
20 more)
Inpatient- Length of stay (follow-up 0.6-7 days; measured with: days; range of scores: 0.5-7; Better indicated by lower values)
8
randomized serious3 no serious
no serious
no serious
none
322
311
MD 1.08
CRITICAL
trials
inconsistency indirectness imprecision
lower MODERATE
(0.39
lower to
0.04
higher)
1
Two of the studies (inclusive of ~ 7% of the subjects) did not report on all outcomes.
2
Two of the studies for this outcome (inclusive of ~ 16% of subjects) did not report on all outcomes.
3
Three of the eight studies had risk of bias (inclusive of ~36% of subjects)
Appendix F
Question 7: For the child who presents with the symptoms of bronchiolitis should short acting beta agonists be used in the
inpatient or outpatient settings?

GRADEProTable:
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Quality assessment
Gadomski, & Brower (2010)
No of
studies

Design

No of patients

Effect

Relative
Risk of
Other
Short acting
Inconsistency Indirectness Imprecision
Control (95% Absolute
bias
considerations bronchodilators
CI)

Quality Importance

Oxygen Saturation by pulse oximetry inpatient and outpatient (follow-up 40-2880 Minutes1; measured with: SpO2; range of scores: 88.5498.8; Better indicated by higher values)
15

randomized no
serious2
serious
trials
risk of
bias

no serious
indirectness

serious3

none

636

546

-

MD 0.45
lower
(0.96
lower to
0.05
higher)

CRITICAL
LOW

Oxygen saturation by pulse oximetry, inpatients only (follow-up 40-2880 minutes; measured with: SpO2; range of scores: 93-97.2; Better
indicated by higher values)
10

randomized serious1 serious
trials

no serious
indirectness

no serious
imprecision

none

230

208

-

MD 0.29
lower
(1.1
lower to
0.51
higher)

CRITICAL
LOW

Oxygen saturation by pulse oximetry in outpatients (follow-up 60-120 minutes4; measured with: SpO2; Better indicated by lower values)
9

randomized serious serious2,4
trials

no serious
indirectness

very serious3 none

406

350

-

MD 0.57
lower VERY LOW
(1.13
lower to
0 higher)
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CRITICAL

No improvement in clinical score inpatient (measured with: improvement in clinical score; range of scores: 0.58-6.17; Better indicated by
lower values)
randomized no
serious2
serious
trials
risk of
bias

7

no serious
indirectness

no serious
imprecision

none

239

157

-

SMD 0.20
CRITICAL
lower MODERATE
(0.43
lower to
0.03
higher)

Duration of hospitalization (follow-up 4.5-2.17 days; measured with: hours; range of scores: 2.17-4.5; Better indicated by lower values)
randomized no
serious2
serious
trials
risk of
bias

5

no serious
indirectness

no serious
imprecision

none

220

129

-

MD 0.06
CRITICAL
higher MODERATE
(0.27
lower to
0.39
higher)

Time to resolution of illness (measured with: days; range of scores: 5-8.9; Better indicated by lower values)
randomized no
no serious
serious inconsistency
trials
risk of
bias

2

1
2
3
4
5

no serious
indirectness

serious5

none

134

135

-

MD 0.29
CRITICAL
higher MODERATE
(0.43
lower to
1 higher)

Six of ten inpatient studies gave the time outcomes were assessed.
Wide range of time to assessment, varying intervals between doses, different doses
There is greater precision in the inpatient studies than in the outpatient studies. Confidence intervals are wider in the outpatient studies.
Only two outpatient studies described length of follow up
Only two studies, low number of subjects

Search Results: A Cochrane Systematic Review Gadomski, & Brower (2010) is the source of evidence for this question
Synthesis Author(s): EBP Scholar, (Allen, N. H)
Date: 2012-06-20
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Appendix G
Question 8: For the child who presents with the symptoms of bronchiolitis, should antibiotics be used in the inpatient or
outpatient settings?

GRADEPro Table
Quality assessment

No of patients

Effect

Quality Importance
Relative
No of
Risk of
Other
Design
Inconsistency Indirectness Imprecision
Antibiotics Control (95% Absolute
studies
bias
considerations
CI)
Duration of symptoms (follow-up 3-10 days; measured with: days; range of scores: 4.62-9.7; Better indicated by lower values)
2
randomized no serious no serious
no serious
no serious
none
60
63
MD 0.32
CRITICAL
trials
risk of
inconsistency indirectness imprecision
higher
HIGH
bias1
(1.14
lower to
1.78
higher)
Length of stay (follow-up 2-6 days; measured with: days; range of scores: 2.13-5.82; Better indicated by lower values)
3
randomized serious1,2,3 no serious
no serious
no serious
none
143
145
MD 0.34
CRITICAL
trials
inconsistency indirectness imprecision
higher MODERATE
(0.71
lower to
1.38
higher)
Re-admissions (follow-up 3 weeks; assessed with: Count)
1
randomized serious4 no serious
no serious
no serious
none
1/12
4/9
OR 0.11
364
CRITICAL
trials
inconsistency indirectness imprecision
(8.3%) (44.4%) (0.01 to fewer per MODERATE
1.29)
1000
(from 437
fewer to
63 more)
Deaths (assessed with: Count)
5
randomized serious1,2,3 no serious
no serious
no serious
none
0/331
212/0
-5
CRITICAL
trials
inconsistency indirectness imprecision
(0%)
(0%)
MODERATE
Synthesis Author(s) EBP Scholars (Allen, N. H.)
Date: 2012-12-02

66

Search Strategy performed:
((((("Anti-Bacterial Agents"[Mesh] OR "Anti-Bacterial Agents"[Pharmacological Action]) OR "Macrolides"[Majr]) OR "Penicillins"[Mesh]) OR
"Tetracyclines"[Mesh]) OR "Cephalosporins"[Majr]) AND ("Bronchiolitis"[Mesh] OR "Bronchiolitis, Viral"[Mesh]) AND ("child"[MeSH Terms] OR
"child"[All Fields])
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